Data / Research funding / Opioid Misuse and Addiction
Opioid Misuse and Addiction: 1,943 NIH awards ($3.2B) to 432 organizations
1,943 NIH awards ($3.2B) in the NIH spending category Opioid Misuse and Addiction, to 432 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 1,943 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| NIDA Clinical Trials Network: New York Node (CTN-0139, CTN-0155, CTN-Biostats) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $66,452,521 | March 1, 2025 | February 29, 2032 | MCNEELY, JENNIFER | reporter.nih.gov |
| CTN New England Consortium Node | NIH | National Institute on Drug Abuse | 2021 to 2025 | $58,365,118 | March 1, 2025 | February 29, 2032 | D'ONOFRIO, GAIL | reporter.nih.gov |
| NIDA Clinical Trials Network: Big South/West Node (CTN-0132 and CTN-0139) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $43,417,361 | March 1, 2025 | February 28, 2032 | TRIVEDI, MADHUKAR H. | reporter.nih.gov |
| CCC TO 11 - CTN-0145: STANDARD VERSUS HIGH DOSE ED-INITIATED BUPRENORPHINE INDUCTION. POP: 8/28/23 - 8/27/27. | NIH | National Institute on Drug Abuse | 2021 to 2025 | $33,434,913 | August 28, 2023 | August 27, 2026 | JELSTROM, EVE | reporter.nih.gov |
| CHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York State | NIH | National Institute on Drug Abuse | 2021 to 2023 | $32,731,263 | September 15, 2023 | March 31, 2024 | EL-BASSEL, NABILA | reporter.nih.gov |
| MassHEAL - Reducing overdose deaths by 40% (2019-2023) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $29,970,213 | September 15, 2023 | March 31, 2024 | SAMET, JEFFREY H. | reporter.nih.gov |
| RADX BLUEPRINT MEDTECH TRANSLATOR COHORT 2 - COMMERCIALIZATION CENTER - HEAL | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $27,543,152 | June 2, 2025 | June 1, 2026 | reporter.nih.gov | |
| Optimizing HEALing in Ohio Communities (OHiO)-Health Equity Supplement | NIH | National Institute on Drug Abuse | 2021 to 2023 | $25,859,414 | September 15, 2023 | March 31, 2024 | FREISTHLER, BRIDGET J | reporter.nih.gov |
| Data Coordinating Center (DCC) for the Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial (NOWS PhaCET) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $25,628,714 | September 20, 2021 | August 31, 2027 | DAS, ABHIK | reporter.nih.gov |
| NorthStar Node of the NIDA Clinical Trials Network | NIH | National Institute on Drug Abuse | 2021 to 2025 | $22,374,119 | September 1, 2015 | February 29, 2032 | BART, GAVIN | reporter.nih.gov |
| SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP) | NIH | National Institute on Drug Abuse | 2024 to 2025 | $21,254,211 | September 6, 2024 | September 5, 2026 | HANANIA, TALEEN | reporter.nih.gov |
| A Strategy for Heal Federated Data Ecosystem | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $21,063,286 | February 18, 2021 | April 30, 2026 | GOSWAMI, SUPARNA | reporter.nih.gov |
| JCOIN Phase II Coordination and Translation Center | NIH | National Institute on Drug Abuse | 2021 to 2025 | $18,785,790 | September 30, 2019 | May 31, 2029 | TAXMAN, FAYE S | reporter.nih.gov |
| The Ohio Valley Node of the Clinical Trials Network (CTN-0153) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $18,588,752 | March 1, 2025 | February 29, 2032 | WINHUSEN, T JOHN | reporter.nih.gov |
| Northeast Node of the National Drug Abuse Treatment Clinical Trials Network | NIH | National Institute on Drug Abuse | 2021 to 2025 | $17,509,561 | March 1, 2025 | February 28, 2030 | MARSCH, LISA A. | reporter.nih.gov |
| HEALing Communities Study Health Equity Research | NIH | National Institute on Drug Abuse | 2021 to 2023 | $15,117,207 | April 1, 2019 | September 29, 2024 | OGA, EMMANUEL AJA | reporter.nih.gov |
| Arylepoxamides: A new class of potent, safer analgesics | NIH | National Institute on Drug Abuse | 2021 to 2023 | $13,729,307 | December 15, 2018 | August 31, 2025 | REICH, JEFFREY | reporter.nih.gov |
| Integrated Care for Chronic Pain and Opioid Use Disorder: The IMPOWR Research Center at Montefiore/Einstein (IMPOWR-ME) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $13,727,424 | September 30, 2021 | July 31, 2027 | STARRELS, JOANNA L. | reporter.nih.gov |
| HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,902,047 | September 30, 2021 | July 31, 2026 | BECKER, WILLIAM C | reporter.nih.gov |
| Supporting Treatment Access and Recovery for Co-Occurring Opioid Use and Mental Health Disorders (STAR-COD) | NIH | National Institute of Mental Health | 2021 to 2024 | $12,719,359 | September 16, 2021 | August 31, 2025 | SMELSON, DAVID A | reporter.nih.gov |
| Tailored Retention and Engagement for Effective integrated Treatment of OUD and Pain (TREETOP) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,656,947 | September 30, 2021 | July 31, 2027 | WINSTANLEY, ERIN L | reporter.nih.gov |
| Center for Addiction and Disease Risk Exacerbation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $12,487,946 | August 1, 2019 | July 31, 2029 | MONTI, PETER M. | reporter.nih.gov |
| The Y-SCORCH Data Generation Center at Yale for Single-Cell Opioid Responses in the Context of HIV | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,331,452 | August 1, 2020 | July 31, 2026 | SPUDICH, SERENA S | reporter.nih.gov |
| Phase III double-blind, randomized controlled trial of suvorexant versus placebo to treat insomnia in persons with opioid use disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $12,205,195 | May 15, 2024 | February 28, 2027 | HUHN, ANDREW S | reporter.nih.gov |
| Evaluation of safety and pharmacokinetics of naltrexone implant | NIH | National Institute on Drug Abuse | 2021 to 2023 | $12,060,583 | September 15, 2018 | February 28, 2026 | BISAGA, ADAM | reporter.nih.gov |
| COBRE Center on Opioids and Overdose | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $11,768,169 | September 1, 2018 | August 31, 2028 | RICH, JOSIAH D | reporter.nih.gov |
| A once-weekly oral methadone for maintenance therapy for opioid use disorder | NIH | National Institute on Drug Abuse | 2021 | $11,699,793 | September 30, 2019 | April 30, 2025 | SCRANTON, RICHARD | reporter.nih.gov |
| Revealing the single cell determinants of brain relevant to persistent HIV infection and opioid use disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $11,197,081 | September 30, 2021 | July 31, 2027 | RANA, TARIQ M | reporter.nih.gov |
| Single cell brain transcriptome changes during chronic HIV infection and opiate use in conventional mice | NIH | National Institute on Drug Abuse | 2021 to 2025 | $11,085,606 | May 15, 2021 | July 31, 2026 | KENNY, PAUL J. | reporter.nih.gov |
| Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose | NIH | National Institute on Drug Abuse | 2022 to 2024 | $11,034,562 | February 1, 2019 | July 31, 2025 | PRAVETONI, MARCO | reporter.nih.gov |
| Center to Advance Research Excellence (OPTIC) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $10,836,251 | August 15, 2018 | June 30, 2028 | STEIN, BRADLEY D | reporter.nih.gov |
| Greater Intermountain Node (CTN-0138) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $10,595,733 | March 1, 2025 | February 29, 2032 | COCHRAN, GERALD T. | reporter.nih.gov |
| Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $10,550,278 | September 30, 2020 | July 31, 2026 | SPRINGER, SANDRA ANN | reporter.nih.gov |
| Integrative Treatment for Achieving Holistic Recovery from Comorbid Chronic Pain and Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $10,475,915 | September 30, 2021 | July 31, 2027 | WITKIEWITZ, KATIE A | reporter.nih.gov |
| Cannabidiol in the treatment of opioid use disorder | NIH | National Institute on Drug Abuse | 2024 | $10,316,590 | September 30, 2019 | August 31, 2027 | HURD, YASMIN L. | reporter.nih.gov |
| PF614-MPAR: clinical development of opioid with oral overdose protection | NIH | National Institute on Drug Abuse | 2024 to 2025 | $9,861,616 | September 1, 2024 | May 31, 2027 | KIRKPATRICK, LYNN | reporter.nih.gov |
| Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $9,732,775 | August 1, 2024 | May 31, 2027 | SHAH, NIKEJ | reporter.nih.gov |
| A novel therapeutic to ameliorate chronic pain and reduce opiate use | NIH | National Institute on Drug Abuse | 2021 to 2024 | $9,323,255 | March 15, 2019 | June 30, 2024 | TABAKOFF, BORIS | reporter.nih.gov |
| Development of a novel drug for treating opioid use disorder | NIH | National Institute on Drug Abuse | 2022 to 2024 | $9,160,866 | March 15, 2019 | August 31, 2025 | SHAH, NIKEJ | reporter.nih.gov |
| Prevention Research Center: Parenting Among Women Who Are Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2023 | $8,972,150 | August 15, 2019 | May 31, 2025 | LEVE, LESLIE DIANE | reporter.nih.gov |
| Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $8,690,640 | July 15, 2015 | April 30, 2030 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| TCN PATHS Supplemental funding | NIH | National Institute on Drug Abuse | 2021 to 2024 | $8,572,442 | July 15, 2019 | April 30, 2026 | WANG, EMILY AI-HUA | reporter.nih.gov |
| Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man | NIH | National Institute on Drug Abuse | 2024 to 2025 | $8,480,887 | September 30, 2019 | April 30, 2027 | GRIGSON, PATRICIA SUE | reporter.nih.gov |
| Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials | NIH | National Institute on Drug Abuse | 2022 | $8,267,350 | September 30, 2022 | September 29, 2025 | PRAVETONI, MARCO | reporter.nih.gov |
| Uncovering HIV/opioid effects in the brain at the single cell level: transcription, chromatin accessibility, and reservoir analysis in the SIV/cART/morphine/rhesus monkey model | NIH | National Institute on Drug Abuse | 2021 to 2025 | $8,243,787 | August 15, 2021 | June 30, 2027 | FOX, HOWARD S | reporter.nih.gov |
| Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone? | NIH | National Institute on Drug Abuse | 2023 to 2025 | $8,178,365 | September 30, 2019 | August 31, 2026 | KAMPMAN, KYLE MATTHEW | reporter.nih.gov |
| 14/24 The Healthy Brain & Child Development National Consortium | NIH | National Institute on Drug Abuse | 2021 to 2025 | $7,959,706 | September 30, 2021 | June 30, 2027 | BANDOLI, GRETCHEN E. | reporter.nih.gov |
| Using Implementation Interventions and Peer Recovery Support to Improve Opioid Treatment Outcomes in Community Supervision | NIH | National Institute on Drug Abuse | 2021 to 2024 | $7,947,350 | August 1, 2019 | April 30, 2025 | MARTIN, ROSEMARIE A | reporter.nih.gov |
| Development of SBS-226, a MOR agonist / DOR antagonist, for OUD | NIH | National Institute on Drug Abuse | 2024 to 2025 | $7,941,988 | September 30, 2024 | August 31, 2027 | REICH, JEFFREY | reporter.nih.gov |
| Development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing relapse and overdose | NIH | National Institute on Drug Abuse | 2024 to 2025 | $7,874,666 | August 15, 2024 | December 31, 2027 | FRANCE, CHARLES P | reporter.nih.gov |
| 16/24 Healthy Brain and Child Development National Consortium | NIH | National Institute on Drug Abuse | 2021 to 2025 | $7,814,498 | September 30, 2021 | June 30, 2026 | FOX, NATHAN A | reporter.nih.gov |
| Greater Southern California Node of the Clinical Trials Network | NIH | National Institute on Drug Abuse | 2021 to 2025 | $7,788,993 | June 1, 2019 | February 29, 2032 | MOONEY, LARISSA JEANETTE | reporter.nih.gov |
| Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | NIH | National Institute on Drug Abuse | 2021 to 2023 | $7,640,612 | May 1, 2023 | April 30, 2026 | GORDON, MICHAEL SCOTT | reporter.nih.gov |
| Reducing Opioid Mortality in Illinois (ROMI) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $7,594,077 | July 15, 2019 | April 30, 2025 | POLLACK, HAROLD ALEXANDER | reporter.nih.gov |
| Health Systems Node of the NIDA Clinical Trials Network (CTN Project: CTN-141 Hlth Ins Instability) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $7,514,766 | March 1, 2025 | February 29, 2032 | CAMPBELL, CYNTHIA I | reporter.nih.gov |
| Western States Node of the National Drug Abuse Treatment Clinical Trials Network (CTN-139) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $7,354,769 | March 1, 2025 | March 1, 2032 | KORTHUIS, PHILIP TODD | reporter.nih.gov |
| Improving quality measurement for opioid use disorder treatment using a multi-state Medicaid research network | NIH | National Institute on Drug Abuse | 2023 to 2025 | $7,124,763 | September 30, 2023 | August 31, 2028 | DONOHUE, JULIE MARIE | reporter.nih.gov |
| A comprehensive dissection of cell types, circuits and molecular adaptations during opioid use | NIH | National Institute on Drug Abuse | 2021 to 2025 | $7,041,006 | June 1, 2021 | March 31, 2027 | SCHERRER, GREGORY | reporter.nih.gov |
| Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder | NIH | National Institute on Drug Abuse | 2023 to 2024 | $6,903,733 | August 15, 2023 | July 31, 2026 | REICH, JEFFREY | reporter.nih.gov |
| Person-centered quality measurement and management in a system for addictions treatment in New York State | NIH | National Institute on Drug Abuse | 2023 to 2025 | $6,873,344 | September 30, 2023 | August 31, 2028 | NEIGHBORS, CHARLES J | reporter.nih.gov |
| Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism | NIH | National Institute on Drug Abuse | 2021 to 2024 | $6,868,774 | April 1, 2020 | January 31, 2026 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Duke HEAL R-DEC | NIH | Office of the Director, National Institutes of Health | 2022 to 2023 | $6,823,028 | September 23, 2022 | June 30, 2025 | HORNIK, CHRISTOPH | reporter.nih.gov |
| Implementing and Personalizing Best-In-Class Opioid-sparing Pain Management for Major Inpatient Surgeries in Children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $6,720,269 | September 5, 2024 | August 31, 2029 | SADHASIVAM, SENTHILKUMAR | reporter.nih.gov |
| An Intranasal GDNF Gene Therapy for Opioid Relapse Reduction | NIH | National Institute on Drug Abuse | 2021 | $6,693,512 | September 15, 2021 | August 31, 2025 | WASZCZAK, BARBARA LEE | reporter.nih.gov |
| Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD) | NIH | National Institute on Drug Abuse | 2023 to 2024 | $6,654,182 | August 15, 2023 | July 31, 2025 | GRIECO, JOSEPH | reporter.nih.gov |
| HEAL Data2Action Modeling and Economic Resource Center | NIH | National Institute on Drug Abuse | 2022 to 2025 | $6,550,146 | September 30, 2022 | August 31, 2027 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder | NIH | National Institute on Drug Abuse | 2022 | $6,445,203 | July 15, 2022 | June 30, 2025 | COSFORD, NICHOLAS DAVID | reporter.nih.gov |
| Impact of maternal substance use on offspring neurobehavioral development | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $6,439,263 | September 1, 2023 | August 31, 2026 | EDLOW, ANDREA GOLDBERG | reporter.nih.gov |
| Evaluation of psilocybin as an adjunctive treatment for opioid use disorder in methadone-maintained patients who continue to use illicit opioids | NIH | National Institute on Drug Abuse | 2024 to 2025 | $6,417,488 | September 30, 2024 | August 31, 2026 | BOGENSCHUTZ, MICHAEL PARKS | reporter.nih.gov |
| Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders | NIH | National Institute on Drug Abuse | 2023 to 2024 | $6,363,247 | September 30, 2019 | August 31, 2025 | JACKSON, MICHAEL | reporter.nih.gov |
| Southeast Enrollment Center Consortium 2 (SEEC-2) | NIH | Office of the Director, National Institutes of Health | 2024 to 2025 | $6,360,000 | July 1, 2024 | June 30, 2026 | ZUCHNER, STEPHAN | reporter.nih.gov |
| Naltrexone Transdermal Patch - An Accessible, Patient-Focused Option to Treat OUD Relapse | NIH | National Institute on Drug Abuse | 2022 to 2023 | $6,351,015 | September 30, 2022 | August 31, 2025 | GARDINER, ANDREW | reporter.nih.gov |
| Development of an implantable closed-loop system for delivery of naloxone for the prevention of opioid-related overdose deaths | NIH | National Institute on Drug Abuse | 2021 | $6,275,050 | September 30, 2019 | August 31, 2025 | GEREAU, ROBERT W | reporter.nih.gov |
| Southwest Clinical Trials Node: Clinical Research and Practice to Address Substance Use in Diverse, Rural, and Underserved Populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $6,192,905 | June 1, 2019 | February 29, 2032 | PAGE, KIMBERLY | reporter.nih.gov |
| A Therapeutic Agent to Lower the Level of Synthetic Opioids in the Body | NIH | National Institute on Drug Abuse | 2023 to 2024 | $6,087,655 | September 1, 2023 | August 31, 2025 | LI, XINHUA | reporter.nih.gov |
| MIRHIQL Resource Center for Improving Quality of Life with Chronic Pain (MRC) | NIH | National Institute on Drug Abuse | 2023 | $5,978,096 | August 15, 2023 | July 31, 2028 | ADAMS, MEREDITH C. B. | reporter.nih.gov |
| Penn PET Addiction Center of Excellence (PACE) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $5,914,143 | August 15, 2019 | June 30, 2025 | MACH, ROBERT H | reporter.nih.gov |
| Defining the impact of drug use on immune function and fitness against HIV-1 | NIH | National Institute on Drug Abuse | 2021 to 2025 | $5,880,000 | May 1, 2021 | April 30, 2026 | SHALEK, ALEX K | reporter.nih.gov |
| Non-Invasive Vagal Nerve Stimulation in Patients with Opioid Use Disorders | NIH | National Institute on Drug Abuse | 2023 to 2025 | $5,776,792 | August 15, 2020 | April 30, 2027 | BREMNER, JAMES DOUGLAS | reporter.nih.gov |
| Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $5,664,540 | March 1, 2025 | February 29, 2032 | HATCH, MARY AKIKO | reporter.nih.gov |
| Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2024 | $5,635,650 | September 30, 2018 | August 31, 2025 | REZAI, ALI R | reporter.nih.gov |
| Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | NIH | National Institute on Drug Abuse | 2021 to 2022 | $5,613,312 | September 30, 2020 | June 30, 2024 | STEVENS, MISTY WARD | reporter.nih.gov |
| HEAL Accelerator: Leveraging Partnerships and Targeted Dissemination to Advance Uptake | NIH | Office of the Director, National Institutes of Health | 2022 to 2023 | $5,606,461 | September 23, 2022 | August 31, 2025 | TAXMAN, FAYE S | reporter.nih.gov |
| Preclinical Development of Novel Dual OXR/KOR Antagonists for Treatment of Substance Use Disorder | NIH | National Institute on Drug Abuse | 2021 | $5,598,515 | September 30, 2021 | September 29, 2025 | BUTERA, JOHN A | reporter.nih.gov |
| PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial | NIH | National Institute on Drug Abuse | 2021 to 2022 | $5,585,570 | September 15, 2018 | December 31, 2023 | KIRKPATRICK, LYNN | reporter.nih.gov |
| Improving Retention across the OUD Service Cascade upon Re-entry from Jail using Recovery Management Checkups | NIH | National Institute on Drug Abuse | 2021 to 2023 | $5,523,458 | July 15, 2019 | April 30, 2026 | DENNIS, MICHAEL L. | reporter.nih.gov |
| JCOIN data curation and archiving | NIH | National Institute on Drug Abuse | 2024 to 2025 | $5,521,141 | June 15, 2019 | May 31, 2029 | SCHNEIDER, JOHN | reporter.nih.gov |
| Facilitating Opioid Care Connections: System level strategies to improve use of MAT and movement through the opioid care cascade for defendants in a new Opioid Court system | NIH | National Institute on Drug Abuse | 2021 to 2023 | $5,473,502 | July 15, 2019 | April 30, 2026 | ELKINGTON, KATHERINE S | reporter.nih.gov |
| Great Lakes & Mid-Atlantic Node (GLMN) of the NIDA CTN (CTN-0144) | NIH | National Institute on Drug Abuse | 2022 to 2025 | $5,408,561 | March 1, 2025 | February 29, 2032 | KARNIK, NIRANJAN SUBHASH | reporter.nih.gov |
| CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse | NIH | National Institute on Drug Abuse | 2021 | $5,400,000 | September 30, 2021 | May 31, 2023 | IREDALE, PHILIP | reporter.nih.gov |
| CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse | NIH | National Institute on Drug Abuse | 2023 to 2024 | $5,400,000 | September 30, 2021 | May 20, 2025 | SUIDAN, GEORGETTE | reporter.nih.gov |
| Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome | NIH | National Institute on Drug Abuse | 2021 | $5,353,314 | September 30, 2021 | August 31, 2025 | GULLO, KRISTEN LEANN | reporter.nih.gov |
| Development of a Potent and Selective Nav1.8 inhibitor for the Treatment of Acute and Chronic Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders | NIH | National Institute on Drug Abuse | 2023 | $5,341,667 | May 15, 2023 | April 30, 2025 | HUNTER, JOHN CURETON | reporter.nih.gov |
| GATHER: Growing a Tribal Healing Effort through Research | NIH | National Institute on Drug Abuse | 2024 to 2025 | $5,340,103 | August 1, 2024 | July 31, 2026 | PARKER, MYRA ELIZABETH | reporter.nih.gov |
| Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDS | NIH | National Institute on Drug Abuse | 2021 to 2024 | $5,321,290 | March 1, 2015 | April 30, 2026 | HAYASHI, KANNA | reporter.nih.gov |
| SOAR: Smartphones for Opioid Addiction Recovery | NIH | National Institute on Drug Abuse | 2021 to 2025 | $5,292,761 | August 15, 2021 | May 31, 2027 | GLIMCHER, PAUL W | reporter.nih.gov |
| Kentucky Women's Justice Community Opioid Innovation Network (WJCOIN) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $5,280,405 | July 15, 2019 | April 30, 2026 | STATON, MICHELE | reporter.nih.gov |
| A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder. | NIH | National Institute on Drug Abuse | 2021 to 2022 | $5,265,428 | August 15, 2021 | March 31, 2024 | GURRELL, IAN | reporter.nih.gov |
| Reducing variation in access to medications for opioid use disorder in Medicaid | NIH | National Institute on Drug Abuse | 2022 to 2025 | $5,252,187 | September 1, 2022 | July 31, 2026 | DONOHUE, JULIE MARIE | reporter.nih.gov |
| High-Resolution, Spinal Cord Stimulation for Non-Opioid Treatment of Neuropathic Pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $5,225,127 | January 1, 2025 | April 30, 2025 | MCLAUGHLIN, BRYAN L | reporter.nih.gov |
| Collaborative to understand impacts of early preventive interventions on suicide and overdose mortality using data harmonization methodology | NIH | National Institute of Mental Health | 2024 to 2025 | $5,154,254 | August 9, 2024 | May 31, 2028 | WILCOX, HOLLY C | reporter.nih.gov |
| Appalachian Node | NIH | National Institute on Drug Abuse | 2021 to 2025 | $5,126,241 | June 15, 2019 | February 29, 2032 | LIEBSCHUTZ, JANE M. | reporter.nih.gov |
| HEAL Research on Interventions for Stability and Engagement (RISE) Network Coordination Center | NIH | National Institute on Drug Abuse | 2024 to 2025 | $5,088,719 | September 30, 2022 | June 30, 2027 | CANCE, JESSICA DUNCAN | reporter.nih.gov |
| Fentalog II: Medical Consequences of Novel Fentanyl Analog Overdose Using the Toxicology Investigators Consortium (TOXIC) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $5,080,519 | April 1, 2020 | March 31, 2030 | MANINI, ALEX FRANCIS | reporter.nih.gov |
| Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,952,252 | August 1, 2019 | June 30, 2025 | MONTANER, LUIS J | reporter.nih.gov |
| HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On | NIH | National Institute on Drug Abuse | 2023 to 2025 | $4,935,947 | September 30, 2023 | August 31, 2028 | MARK, TAMI L | reporter.nih.gov |
| Injectable naltrexone 2-month depot formulations | NIH | National Institute on Drug Abuse | 2022 to 2024 | $4,908,655 | April 1, 2019 | December 31, 2025 | PARK, KINAM | reporter.nih.gov |
| Nonpharmacologic Pain Management in FQHC primary care clinics | NIH | National Institute of Nursing Research | 2021 to 2024 | $4,905,424 | September 25, 2020 | August 31, 2026 | FRITZ, JULIE M | reporter.nih.gov |
| Rapid Actionable Data for Opioid Response in Kentucky (RADOR-KY) | NIH | National Institute on Drug Abuse | 2022 to 2025 | $4,881,729 | September 30, 2022 | August 31, 2027 | SLAVOVA, SVETLA STEFANOVA | reporter.nih.gov |
| Ending HIV: Bringing Integrated Prevention and Treatment Services to People Who Use Drugs Where They Live | NIH | National Institute on Drug Abuse | 2022 to 2025 | $4,857,421 | June 15, 2022 | May 31, 2027 | SPRINGER, SANDRA ANN | reporter.nih.gov |
| Massachusetts Justice Community Opioid Innovation Network (JCOIN) Clinical Research Center | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,788,260 | July 15, 2019 | April 3, 2025 | FRIEDMANN, PETER D | reporter.nih.gov |
| Integrating Nonpharmacologic Strategies for Pain with Inclusion, Respect, and Equity (INSPIRE): Tailored digital tools, telehealth coaching, and primary care coordination | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $4,783,072 | August 15, 2022 | July 31, 2027 | SATTERFIELD, JASON M | reporter.nih.gov |
| MEB-1170: A New Chemical Entity for the Treatment of Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2025 | $4,710,576 | July 1, 2025 | June 30, 2027 | KUO, LAWRENCE C | reporter.nih.gov |
| Integrating Addiction and Infectious Diseases Services into Primary Care in Rural Settings | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,664,222 | August 1, 2021 | May 31, 2027 | ALTICE, FREDERICK LEWIS | reporter.nih.gov |
| Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy - Yale Resource Center (MIRHIQL-YRC) | NIH | National Institute on Drug Abuse | 2023 | $4,626,338 | August 15, 2023 | July 31, 2026 | BECKER, WILLIAM C | reporter.nih.gov |
| Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics | NIH | National Institute on Drug Abuse | 2024 to 2025 | $4,623,799 | September 30, 2019 | December 31, 2026 | CORTES-PUCH, IRENE | reporter.nih.gov |
| IMPETUS: Integrated Mechanisms, Phenotypes, and Translational Underpinnings of Chronic Pain after Surgery | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $4,618,885 | September 18, 2024 | August 31, 2027 | HAROUTOUNIAN, SIMON | reporter.nih.gov |
| HEALing Measurement Center: Enhancing Opioid Use Disorder Recovery through Measurement Based Care | NIH | National Institute on Drug Abuse | 2023 to 2025 | $4,598,946 | September 30, 2023 | August 31, 2028 | CLOUTIER, RENEE M | reporter.nih.gov |
| Building Social and Structural Connections for the Prevention of OUD among Youth Experiencing Homelessness: An RCT Examining Biopsychosocial Mechanisms | NIH | National Institute on Drug Abuse | 2023 to 2025 | $4,538,190 | September 30, 2023 | July 31, 2028 | FORD, JODI L. | reporter.nih.gov |
| A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $4,514,823 | April 1, 2019 | April 30, 2027 | COHEN, STEVEN M | reporter.nih.gov |
| Opioid use disorders: UF Pharmacy medications discovery and development | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,479,677 | December 15, 2018 | November 30, 2024 | MCCURDY, CHRISTOPHER R | reporter.nih.gov |
| Promoting Community Wellbeing Through Indigenous Science and Healing | NIH | National Institute on Drug Abuse | 2024 to 2025 | $4,470,789 | August 15, 2024 | July 31, 2026 | MCDONELL, MICHAEL G | reporter.nih.gov |
| Non-pharmacological Options in postoperative Hospital-based And Rehabilitation pain Management (NOHARM) pragmatic clinical trial | NIH | National Institute on Aging | 2021 to 2023 | $4,429,006 | September 30, 2019 | August 31, 2025 | CHEVILLE, ANDREA LYNNE | reporter.nih.gov |
| Impact of a novel HIV peer navigationand overdose prevention intervention on engagement in the HIV prevention and treatment cascade. | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,391,293 | September 1, 2021 | June 30, 2027 | SHERMAN, SUSAN G. | reporter.nih.gov |
| Methocinnamox (MCAM): A novel opioid receptor antagonist | NIH | National Institute on Drug Abuse | 2023 | $4,373,045 | July 1, 2023 | June 30, 2024 | FRANCE, CHARLES P | reporter.nih.gov |
| Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (KeY Treat) Study | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,371,481 | September 30, 2018 | July 31, 2025 | HAVENS, JENNIFER R | reporter.nih.gov |
| WF DISC: Navigating Data Solutions for Chronic Pain and Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $4,339,941 | September 30, 2022 | August 31, 2028 | ADAMS, MEREDITH C. B. | reporter.nih.gov |
| Mu Opioid Receptor Modulator Development to Treat Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $4,337,165 | September 30, 2019 | January 31, 2027 | ZHANG, YAN | reporter.nih.gov |
| Single nuclei transcriptome profiling in addiction circuitry of the HIV+ brain | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,310,228 | April 1, 2021 | February 28, 2027 | AKBARIAN, SCHAHRAM | reporter.nih.gov |
| Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,306,927 | September 15, 2018 | August 31, 2023 | KUO, LAWRENCE C | reporter.nih.gov |
| Antibody-based therapy for fentanyl-related opioid use disorder | NIH | National Institute on Drug Abuse | 2023 | $4,202,550 | September 30, 2023 | August 31, 2025 | DESAI, RAJEEV INDRAJIT | reporter.nih.gov |
| Use of Next-Gen Sequencing to Identify Genetic Variants that Influence compulsive Oxycodone Intake in Outbred Rats | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,173,211 | April 1, 2018 | February 29, 2028 | GEORGE, OLIVIER | reporter.nih.gov |
| Promoting HIV risk reduction among people who inject drugs: A stepped care approach using contingency management with PrEP navigation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,159,587 | July 1, 2020 | May 31, 2027 | EDELMAN, E. JENNIFER | reporter.nih.gov |
| Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings | NIH | National Institute on Drug Abuse | 2022 to 2023 | $4,143,992 | September 30, 2019 | August 31, 2025 | GEHLERT, DONALD R | reporter.nih.gov |
| Opiod Analgesic Reduction Study (OARS): Managing Acute Post-Operative Surgical Pain | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2023 | $4,090,798 | August 1, 2020 | July 31, 2025 | FELDMAN, CECILE | reporter.nih.gov |
| Using SMART Design to Identify an Effective and Cost-Beneficial Approach to Preventing OUD in Justice-Involved Youth | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,080,444 | September 30, 2019 | August 31, 2024 | AHRENS, KYM R | reporter.nih.gov |
| Development of Next-generation Pharmacotherapy for Opioid Use Disorders | NIH | National Institute on Drug Abuse | 2022 to 2024 | $4,073,436 | January 1, 2019 | July 31, 2025 | ZAVERI, NURULAIN T | reporter.nih.gov |
| Single nucleus gene expression in moderate and compulsive opioid self-administration in a rodent model of HIV | NIH | National Institute on Drug Abuse | 2023 to 2025 | $4,045,522 | September 1, 2023 | June 30, 2028 | SANNA, PIETRO P | reporter.nih.gov |
| Integrative Single Cell isoform and chromatin accessibility Mapping of Chronic Opioid Exposure in Cognitive Brain Areas in HIV | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,038,720 | September 30, 2021 | June 30, 2027 | TILGNER, HAGEN ULRICH | reporter.nih.gov |
| Increasing Peer Support for OUD Recovery through Digital Health: A National Randomized Controlled Trial | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,035,370 | August 15, 2021 | July 31, 2027 | BEAUDOIN, FRANCESCA | reporter.nih.gov |
| Development of novel therapeutics for opioid dependence | NIH | National Institute on Drug Abuse | 2021 to 2022 | $3,944,970 | September 30, 2018 | August 31, 2024 | KENNY, PAUL J. | reporter.nih.gov |
| Researching Effective Strategies to Prevent Opioid Death (RESPOND) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,943,189 | June 1, 2018 | July 31, 2028 | LINAS, BENJAMIN P. | reporter.nih.gov |
| Making Better Decisions: Policy Modeling for AIDS and Drug Abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,865,844 | September 25, 2022 | January 31, 2029 | OWENS, DOUGLAS K | reporter.nih.gov |
| An automated portable system for detecting and treating opioid induced respiratory depression | NIH | National Institute on Drug Abuse | 2022 to 2024 | $3,830,637 | April 1, 2022 | February 28, 2026 | MACKIE, KENNETH | reporter.nih.gov |
| Immune Dysfunction in HIV+ Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,823,539 | April 15, 2020 | January 31, 2027 | PAHWA, SAVITA | reporter.nih.gov |
| The Emergency Department Longitudinal Integrated Care (ED-LINC) Effectiveness Randomized Trial Targeting Opioid Use and Related Comorbidity from the ED | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,800,864 | August 1, 2021 | June 30, 2027 | WHITESIDE, LAUREN K | reporter.nih.gov |
| Development and Implementation of a Culturally Centered Opioid Prevention Intervention for American Indian/Alaska Native Young Adults in California | NIH | National Institute on Drug Abuse | 2021 to 2023 | $3,791,983 | September 30, 2019 | August 31, 2025 | D'AMICO, ELIZABETH J. | reporter.nih.gov |
| Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,772,066 | April 15, 2017 | July 31, 2027 | BERMAN, JOAN WEINBERGER | reporter.nih.gov |
| 15/24- Healthy Brain and Child Development National Consortium | NIH | National Institute on Drug Abuse | 2021 to 2023 | $3,749,834 | September 30, 2021 | June 30, 2024 | SCOTT, LISA S. | reporter.nih.gov |
| Spatio-temporal Methods for Surveillance of the Opioid Syndemic | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,748,657 | September 1, 2025 | August 31, 2029 | KLINE, DAVID M | reporter.nih.gov |
| Community Randomized Trial in the Cherokee Nation: CONNECT and CMCA for Preventing Drug Misuse among Older Adolescents | NIH | National Institute on Drug Abuse | 2021 to 2023 | $3,708,886 | September 30, 2019 | August 31, 2025 | KOMRO, KELLI ANN | reporter.nih.gov |
| The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,680,536 | April 1, 2020 | May 31, 2029 | HUYBRECHTS, KRISTA F | reporter.nih.gov |
| Collaborative care teams for hospitalized patients with opioid use disorders: Translating evidence into practice | NIH | National Center for Advancing Translational Sciences | 2021 to 2023 | $3,678,409 | June 1, 2020 | May 31, 2025 | DANOVITCH, ITAI | reporter.nih.gov |
| ADAPT: Adaptive Decision support for Addiction Treatment | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,638,873 | September 30, 2023 | July 31, 2028 | MELNICK, EDWARD ROBERT | reporter.nih.gov |
| Evaluating Suvorexant for Sleep Disturbance in Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 | $3,632,165 | April 1, 2019 | August 31, 2025 | HUHN, ANDREW S | reporter.nih.gov |
| Alliance to Disseminate Addiction Prevention and Treatment (ADAPT): A Statewide Learning Health System to Reduce Substance Use among Justice-Involved Youth in Rural Communities. | NIH | National Institute on Drug Abuse | 2021 to 2023 | $3,626,057 | September 30, 2019 | April 30, 2026 | AALSMA, MATTHEW | reporter.nih.gov |
| Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program. | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,603,973 | September 30, 2019 | May 31, 2026 | ALSOP, HUGH WILLIAM | reporter.nih.gov |
| EMBED: Pragmatic trial of user-centered clinical decision support to implement EMergency department-initiated BuprenorphinE for opioid use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2022 | $3,603,411 | April 1, 2018 | September 30, 2024 | MELNICK, EDWARD ROBERT | reporter.nih.gov |
| Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $3,588,425 | March 1, 2024 | October 17, 2025 | MAREK, GERARD JOSEPH | reporter.nih.gov |
| Small molecule modulators of ΔFosB | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,586,553 | July 1, 2016 | March 31, 2027 | RUDENKO, GABRIELLE | reporter.nih.gov |
| Cannabidiol for postoperative Opioid Reduction in primary total Knee arthroplasty – a randomized, 2x2 factorial, double-blind, placebo-controlled clinical trial (The CORK trial) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $3,579,362 | September 18, 2023 | August 31, 2028 | BRUMMETT, CHAD M | reporter.nih.gov |
| Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components | NIH | National Institute on Drug Abuse | 2023 | $3,569,552 | September 15, 2018 | March 31, 2028 | COMER, SANDRA D | reporter.nih.gov |
| Development of a 3-month implantable depot pellet of Naltrexone for the treatment of Opioid Use Disorder. | NIH | National Institute on Drug Abuse | 2021 to 2022 | $3,552,798 | March 1, 2022 | August 31, 2023 | MALLON, ANDREW PETER | reporter.nih.gov |
| Synthetics in Combination (SYNC) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,536,582 | September 30, 2021 | June 30, 2026 | CICCARONE, DANIEL H | reporter.nih.gov |
| Acetylcholine signaling allows cognitive processes in the brain to regulate physiological responses to the environment: the example of central control of opiate tolerance | NIH | National Institute on Drug Abuse | 2021 to 2023 | $3,517,500 | August 15, 2019 | July 31, 2025 | PICCIOTTO, MARINA R | reporter.nih.gov |
| Sleep and circadian rhythm phenotypes and mechanisms associated with opioid use disorder treatment outcomes | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,516,481 | September 30, 2023 | August 31, 2027 | HUHN, ANDREW S | reporter.nih.gov |
| Prescription Opioid Misuse: A Pharmacist-Led Intervention at Point of Service Efficacy Trial | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,513,979 | March 15, 2021 | January 31, 2027 | COCHRAN, GERALD T. | reporter.nih.gov |
| Opioid therapy for pain in individuals with metastatic cancer: benefits, harms and stakeholder perspectives | NIH | National Institute of Nursing Research | 2021 to 2025 | $3,491,253 | September 15, 2021 | June 30, 2027 | WHITE, GRETCHEN | reporter.nih.gov |
| Partnering to Achieve Wellness for Native Americans through Indigenous Knowledge (PAWNIK) | NIH | National Institute on Drug Abuse | 2024 to 2025 | $3,488,602 | September 9, 2024 | August 31, 2026 | D'AMICO, ELIZABETH J. | reporter.nih.gov |
| Center for chronic pain and drug abuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $3,471,757 | September 1, 2018 | June 30, 2025 | APKARIAN, APKAR VANIA | reporter.nih.gov |
| Integrated, Individualized, and Intelligent Prescribing (I3P) Clinical Trial Network | NIH | National Human Genome Research Institute | 2021 to 2024 | $3,458,289 | July 1, 2024 | June 30, 2025 | PETERSON, JOSEPH F. | reporter.nih.gov |
| Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2025 | $3,450,000 | September 15, 2018 | January 31, 2028 | PATEL, RAJESH A | reporter.nih.gov |
| Peer-Delivered, Behavioral Activation Intervention to Improve Polysubstance Use and Retention in Mobile Telemedicine OUD Treatment in an Underserved, Rural Area | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,434,019 | September 30, 2022 | August 31, 2027 | MAGIDSON, JESSICA F | reporter.nih.gov |
| UnityPhilly Response App for Overdose Reversal: Assessing Citywide Effectiveness and Sustainability | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,424,229 | September 30, 2023 | July 31, 2028 | LANKENAU, STEPHEN E | reporter.nih.gov |
| Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials | NIH | National Institute on Drug Abuse | 2025 | $3,410,308 | September 30, 2022 | July 31, 2028 | PRAVETONI, MARCO | reporter.nih.gov |
| Preclinical and clinical evaluation of the NMDA modulator NYX-783 for OUD | NIH | National Institute on Drug Abuse | 2022 | $3,406,895 | September 30, 2019 | September 29, 2025 | SINHA, RAJITA | reporter.nih.gov |
| Integrating Tailored Postoperative Opioid Tapering and Pain Management Support for Patients on Long-Term Opioid Use Presenting for Spine Surgery (MIRHIQL) | NIH | National Institute on Drug Abuse | 2023 | $3,406,550 | August 15, 2023 | July 31, 2026 | HAH, JENNIFER | reporter.nih.gov |
| Genetics of oxycodone intake in a hybrid rat diversity panel. | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,392,750 | April 15, 2021 | January 31, 2027 | SHARP, BURT M | reporter.nih.gov |
| Evaluating the impact of fentanyl test strip use among rural and urban populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,392,442 | July 1, 2021 | April 30, 2027 | MICHAELS, NICHOLE L | reporter.nih.gov |
| Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,386,037 | September 1, 2022 | June 30, 2027 | COPENHAVER, MICHAEL | reporter.nih.gov |
| Evaluation of a community-based education, navigation, and support (CENS) intervention to reduce opioid-related harms among military veterans | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,379,762 | September 30, 2021 | July 31, 2027 | BENNETT, ALEXANDER S | reporter.nih.gov |
| Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $3,353,166 | August 4, 2022 | April 30, 2027 | SUDA, KJ | reporter.nih.gov |
| Leveraging regulatory flexibility for methadone take-home dosing to improve retention in treatment for opioid use disorder: A stepped-wedge randomized trial to facilitate clinic level changes | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,350,010 | September 30, 2022 | August 31, 2027 | NEIGHBORS, CHARLES J | reporter.nih.gov |
| Promoting remote and secondary risk prevention services in rural settings | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,349,340 | September 30, 2022 | July 31, 2027 | PHO, MAI TUYET | reporter.nih.gov |
| Fatal Overdose Review Teams - Research to Enhance Surveillance Systems (FORTRESS) | NIH | National Institute on Drug Abuse | 2024 | $3,330,528 | September 30, 2022 | August 31, 2027 | AALSMA, MATTHEW | reporter.nih.gov |
| Wake Forest IMPOWR Dissemination Education and Coordination Center (IDEA-CC) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $3,329,368 | September 30, 2021 | July 31, 2027 | ADAMS, MEREDITH C. B. | reporter.nih.gov |
| Evaluating naloxone-on-release from incarceration as community overdose prevention | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,318,365 | June 15, 2022 | April 30, 2027 | DAVIDSON, PETER JOHN | reporter.nih.gov |
| Phase 1 and 2 studies of sublingual dexmedetomidine, an alpha 2 adrenergic agonist, for treating opioid withdrawal | NIH | National Institute on Drug Abuse | 2022 | $3,312,204 | August 1, 2022 | July 31, 2025 | LEVIN, FRANCES RUDNICK | reporter.nih.gov |
| Discovery of PSD95 protein-protein interaction inhibitors as novel non-opioid analgesics | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,311,688 | March 1, 2021 | February 28, 2026 | FLORIO, STEPHANIE K | reporter.nih.gov |
| Medications for opioid use disorder differentially modulate intrinsically photosensitive retinal ganglion cell function, sleep, and circadian rhythms: implications for treatment | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,303,776 | September 30, 2023 | August 31, 2027 | CROPSEY, KAREN L | reporter.nih.gov |
| Perioperative Precision Medicine: Translating Science to Clinical Practice to Improve Safety and Efficacy of Opioids in Neonates, Children and Nursing Mothers | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $3,295,714 | August 3, 2022 | April 30, 2027 | SADHASIVAM, SENTHILKUMAR | reporter.nih.gov |
| Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,276,074 | September 1, 2021 | June 30, 2027 | MCGOVERN, MARK P | reporter.nih.gov |
| PrEP and MOUD Rapid Access for Persons who Inject Drugs: the CHORUS+ Study | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,275,988 | September 1, 2023 | June 30, 2028 | ASSOUMOU, SABRINA A | reporter.nih.gov |
| The impact of central sleep apnea in patients receiving medications for opioid use disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,271,652 | September 30, 2023 | August 31, 2027 | PATEL, SANJAY R | reporter.nih.gov |
| Clinical markers of neonatal opioid withdrawal syndrome: onset, severity and longitudinal neurodevelopmental outcome | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,270,993 | April 1, 2020 | February 28, 2026 | LESTER, BARRY M. | reporter.nih.gov |
| Development of Hsp90 Isoform- Selective Inhibitors as a Novel Opioid Dose-Reduction Therapy | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,250,198 | July 15, 2021 | April 30, 2027 | STREICHER, JOHN MICHAEL | reporter.nih.gov |
| Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,245,619 | September 30, 2023 | August 31, 2027 | CARSKADON, MARY A | reporter.nih.gov |
| Improving Postpartum Contraceptive Decision-Making Among Women With Substance Use Disorders | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,238,862 | June 1, 2021 | March 31, 2027 | KRANS, ELIZABETH E | reporter.nih.gov |
| Functional and Genomic Signatures of Escalated Fentanyl Use | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,237,608 | March 15, 2021 | December 31, 2026 | TURNER, JILL R. | reporter.nih.gov |
| Implementation of telemedicine and social network driven HIV service uptake for comprehensive HIV service integration in rural syringe service programs | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,234,132 | August 1, 2023 | May 31, 2028 | FALADE-NWULIA, OLUWASEUN | reporter.nih.gov |
| Telemedicine for Treatment of Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,194,573 | July 1, 2019 | May 31, 2028 | HUSKAMP, HAIDEN A. | reporter.nih.gov |
| Optimization and multi-site feasibility of yoga for chronic pain in people in treatment for opioid use disorder | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $3,193,009 | April 1, 2020 | March 31, 2026 | UEBELACKER, LISA A | reporter.nih.gov |
| Ending the HIV Epidemic in Rural America (EHE-RA): Local Interventions, Co-Epidemics, and Social Determinants | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $3,186,420 | September 23, 2022 | May 31, 2027 | FOJO, ANTHONY TODD | reporter.nih.gov |
| Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia to minimize postoperative opioid requirements | NIH | National Institute on Drug Abuse | 2022 to 2024 | $3,185,967 | September 15, 2020 | June 30, 2025 | LE MAU, TUAN | reporter.nih.gov |
| Evaluating a Mechanistically-Supported Pharmacotherapy to Treat Acute and Protracted Opioid Withdrawal | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,157,348 | August 1, 2022 | September 1, 2025 | BERGERIA, CECILIA | reporter.nih.gov |
| Expansion of Mail-Delivered Harm Reduction Services in the U.S. | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,156,884 | September 30, 2022 | September 29, 2026 | BEHRENDS, CZARINA NAVOS | reporter.nih.gov |
| POWS for NOWS: Using physiomarkers as an objective tool for assessing the withdrawing infant | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 | $3,149,700 | August 1, 2023 | July 31, 2026 | SULLIVAN, BRYNNE ARCHER | reporter.nih.gov |
| Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2023 | $3,145,305 | August 15, 2023 | July 31, 2026 | RADHAKRISHNAN, RUPA | reporter.nih.gov |
| Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for Pain | NIH | National Institute on Drug Abuse | 2025 | $3,138,031 | July 1, 2025 | June 30, 2027 | ASHWORTH, JUDY | reporter.nih.gov |
| Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P) | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,129,999 | September 20, 2022 | February 28, 2026 | NWAOKOBIA, CHARLES CHIEDU | reporter.nih.gov |
| Opiod Analgesic Reduction Study (OARS): Managing Acute Post-Operative Surgical Pain | NIH | National Institute of Dental & Craniofacial Research | 2021 | $3,127,499 | August 1, 2020 | July 31, 2024 | FELDMAN, CECILE | reporter.nih.gov |
| Preferences and predictors driving opioid-involved polysubstance use profiles and trajectories: Implications for improving care | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,119,296 | September 30, 2022 | August 31, 2027 | COUGHLIN, LARA NICOLE | reporter.nih.gov |
| Discriminative Stimulus Effects of Opioid Withdrawal | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,097,773 | May 1, 1995 | December 31, 2026 | FRANCE, CHARLES P | reporter.nih.gov |
| A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,097,234 | September 30, 2023 | June 30, 2029 | GORDON, MICHAEL SCOTT | reporter.nih.gov |
| HEAL - ASSESSMENT OF POTENTIAL SUBSTANCE ABUSE TREATMENT MEDICATIONS IN NONHUMAN PRIMATE MODELS. NIDA REF. NO. N01DA-19-8946; POP: 12/16/2018-12/15/2022. | NIH | National Institute on Drug Abuse | 2022 to 2023 | $3,093,836 | December 16, 2018 | December 15, 2023 | BERGMAN, JACK | reporter.nih.gov |
| Multimodal Analysis of Gestational Health and Placental Injury in Opioid-Affected Pregnancies | NIH | National Institute on Drug Abuse | 2023 | $3,092,159 | August 15, 2023 | July 30, 2026 | OUYANG, YINGSHI | reporter.nih.gov |
| State-level opioid policies and policies that regulate substance use duringpregnancy: a mixed methods exploration of their effects on maternal and infantoutcomes | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,056,493 | August 1, 2022 | June 30, 2027 | MARTINS, SILVIA SABOIA | reporter.nih.gov |
| The short and long-term dynamics of opioid/stimulant use: Mixed methods to inform overdose prevention and treatment related to polysubstance use | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,051,259 | September 30, 2022 | July 31, 2027 | GENBERG, BECKY LYNN | reporter.nih.gov |
| Circuitry dynamics underlying opioid-dependence: Integrating structural, functional, and transcriptomic mechanisms | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,047,206 | September 1, 2022 | May 31, 2027 | CORDER, GREGORY | reporter.nih.gov |
| Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement for Tobacco Dependence and Other Drug use in Methadone Treatment | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,032,237 | September 30, 2022 | August 31, 2027 | COOPERMAN, NINA | reporter.nih.gov |
| A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder | NIH | National Institute on Drug Abuse | 2025 | $3,027,897 | August 15, 2021 | June 30, 2027 | KENNY, PAUL J. | reporter.nih.gov |
| Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,027,776 | September 30, 2022 | July 31, 2027 | ALEXANDER, KAREN | reporter.nih.gov |
| Implementing and evaluating the impact of novel mobile harm reduction services on overdose among women who use drugs: The SHOUT study. | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,024,580 | September 30, 2022 | July 31, 2027 | SHERMAN, SUSAN G. | reporter.nih.gov |
| A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder. | NIH | National Institute on Drug Abuse | 2024 | $3,024,162 | August 15, 2021 | February 28, 2025 | GURRELL, IAN | reporter.nih.gov |
| Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $3,012,228 | August 1, 2022 | August 31, 2026 | TRAYNOR, JOHN R. | reporter.nih.gov |
| POPI: Placenta, Opioids and Perinatal Implications | NIH | National Institute on Drug Abuse | 2023 | $3,011,183 | August 1, 2023 | July 31, 2026 | MESSAOUDI, ILHEM | reporter.nih.gov |
| Mechanisms of repeated opioid use dependent remodeling in respiratory control | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,007,583 | August 5, 2022 | May 31, 2026 | GARCIA, ALFREDO J | reporter.nih.gov |
| The Role of Family Functioning and Race/Ethnicity on the Efficacy of an Opioid Misuse Prevention Videogame Intervention for Adolescents | NIH | National Institute on Drug Abuse | 2021 | $3,004,276 | September 1, 2021 | October 31, 2023 | FIELLIN, LYNN ELIZABETH | reporter.nih.gov |
| Disrupting Social Risk Factors of Health to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,001,349 | September 1, 2023 | August 31, 2027 | SALDANA, LISA | reporter.nih.gov |
| A Novel Reversal Agent for Treatment of Overdose from the Combination of Fentanyl and Xylazine | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,999,483 | August 1, 2024 | July 31, 2026 | LI, XINHUA | reporter.nih.gov |
| Counteracting Structural Barriers to Increase Access to Medications for Opioid Use Disorder (MOUD) Among Unhoused Montanans | NIH | Office of the Director, National Institutes of Health | 2023 to 2025 | $2,999,246 | September 22, 2023 | September 21, 2028 | RAMOS, REBECCA | reporter.nih.gov |
| Improving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with Disability | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,994,575 | September 1, 2022 | June 30, 2027 | CRYSTAL, STEPHEN | reporter.nih.gov |
| THRIVE: Teaching Health promotion and Resilience in Varied Environments: a peer-led intervention following hospital discharge | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,988,641 | September 30, 2022 | July 31, 2027 | WILSON, JACQUELINE DEANNA | reporter.nih.gov |
| Advancing the science on recovery community centers to support persons treated with medications for opioid use disorder | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,982,763 | July 15, 2020 | April 30, 2026 | HOEPPNER, BETTINA B. | reporter.nih.gov |
| Machine-Learning Prediction and Reducing Overdoses with EHR Nudges (mPROVEN) | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,975,448 | September 1, 2017 | April 30, 2027 | GELLAD, WALID F. | reporter.nih.gov |
| Molecular Studies of Cocaine Action in Brain | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,971,622 | August 1, 1991 | January 31, 2026 | NESTLER, ERIC J. | reporter.nih.gov |
| The Youth Opioid Recovery Support (YORS) Intervention: An assertive community treatment model for improving medication adherence in young adults with opioid use disorder | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,958,236 | August 28, 2019 | August 31, 2024 | FISHMAN, MARC | reporter.nih.gov |
| Plasticity of Aversive Salience in Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,956,832 | March 1, 2021 | December 31, 2026 | STEWART, JENNIFER LORRAINE | reporter.nih.gov |
| Addictions treatment organizational response to 2020 public health policy changes: impact on quality of care | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,954,590 | April 1, 2022 | February 28, 2027 | NEIGHBORS, CHARLES J | reporter.nih.gov |
| Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome. | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,947,993 | July 1, 2020 | June 30, 2025 | SHARAREH, SHIVA | reporter.nih.gov |
| NX90: A Treatment for Overdose Caused by High Potency Opioids | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,946,808 | September 30, 2024 | August 31, 2026 | VORONKOV, MICHAEL V. | reporter.nih.gov |
| Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,935,212 | September 30, 2022 | July 31, 2028 | HOCHSTATTER, KARLI RAE | reporter.nih.gov |
| Development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for opioid use disorder | NIH | National Institute on Drug Abuse | 2025 | $2,932,500 | August 1, 2025 | July 31, 2027 | COHEN, STEVEN M | reporter.nih.gov |
| Optimization and Development of Non-Hallucinogenic 5-HT2A/2C Agonists as Opioid Use Disorder Therapeutics | NIH | National Institute on Drug Abuse | 2025 | $2,923,842 | August 15, 2025 | June 30, 2027 | SHORT III, GLENN | reporter.nih.gov |
| The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,923,597 | July 1, 2023 | June 30, 2025 | NWAOKOBIA, CHARLES CHIEDU | reporter.nih.gov |
| Opioid and SUD Data Enclave (O-SUDDEn): Bringing real-time data to the opioid crisis | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,921,106 | September 30, 2022 | August 31, 2027 | FERNANDEZ, SOLEDAD A | reporter.nih.gov |
| Molecular Neurobiology of Human Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,918,959 | July 15, 2021 | March 31, 2027 | HURD, YASMIN L. | reporter.nih.gov |
| Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders | NIH | National Institute on Drug Abuse | 2021 | $2,917,074 | January 1, 2019 | January 2, 2025 | SNYDER, GRETCHEN L | reporter.nih.gov |
| Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents | NIH | National Institute on Drug Abuse | 2024 | $2,916,742 | July 15, 2024 | June 30, 2026 | SCHMIDT, LEE | reporter.nih.gov |
| Assessing the influence of pandemic-era policies on patterns of opioid use disorder care in a national veteran population | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,910,476 | April 1, 2022 | January 31, 2027 | WILLIAMS, EMILY CATERINA | reporter.nih.gov |
| D1 and D2 Dopaminoceptive Ensembles in Limbic Brain Regions in Drug Addiction | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,909,999 | September 1, 2000 | April 30, 2030 | NESTLER, ERIC J. | reporter.nih.gov |
| Assessing the Reach, Effectiveness, and Implementation of Multiple Interventions | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,900,711 | September 30, 2022 | July 31, 2027 | KRAL, ALEXANDER H | reporter.nih.gov |
| Effects of Sleep Disruption on Subjective Responses to Opioid Administration in Patients with Chronic Pain | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,894,566 | May 1, 2019 | February 28, 2026 | SMITH, MICHAEL T | reporter.nih.gov |
| Economic Conditions, Policy Environments, and Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,891,466 | July 1, 2022 | May 31, 2027 | HILL, ELAINE L | reporter.nih.gov |
| Neonatal Opioid Exposure and Withdrawal: Molecular and Behavioral Consequences | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,884,934 | April 1, 2020 | January 31, 2026 | BLENDY, JULIE A | reporter.nih.gov |
| Single Cell Transciptomics of the Opioid Use Disorder and HIV Syndemic in the Human Brain | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,859,989 | September 1, 2022 | August 31, 2025 | CHENG, CHRISTINE | reporter.nih.gov |
| Deterrents for prescription opioid abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,853,877 | September 15, 2015 | May 31, 2027 | FREEMAN, KEVIN B. | reporter.nih.gov |
| Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,842,189 | November 1, 2021 | October 31, 2026 | DAHARI, HAREL | reporter.nih.gov |
| Studying How State and Local Health Services Delivery Policies can Mitigate the Effects of Disasters on Drug Addiction Treatment and Overdose: A Mixed-Methods Study of COVID-19. | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,829,066 | August 1, 2021 | May 31, 2026 | EISENBERG, MATTHEW | reporter.nih.gov |
| Development of Specific Mu Opioid Receptor Antagonists to Reverse the Acute and Chronic Toxicity of Fentanyls | NIH | National Institute on Drug Abuse | 2022 | $2,824,374 | July 1, 2022 | June 30, 2025 | ZHANG, YAN | reporter.nih.gov |
| Transcriptomic single-cell profiling in breathing-specific parabrachial mu-opioid receptor neurons | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,823,224 | July 15, 2022 | May 31, 2027 | HAN, SUNG | reporter.nih.gov |
| Integrated eHealth for HIV and Substance Use Disorders in Justice-involved Women | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,821,947 | September 15, 2022 | June 30, 2027 | MEYER, JAIMIE | reporter.nih.gov |
| Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,819,585 | July 15, 2023 | June 30, 2027 | GREENBERG, MILTON L | reporter.nih.gov |
| Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting. | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,818,821 | July 1, 2022 | December 31, 2026 | MILLER, THOMAS L. | reporter.nih.gov |
| Improving pain management and opioid safety through a systemwide, data driven evaluation of the CDC opioid prescribing guideline best practices and the use of Clinical Decision Support | NIH | National Institute on Drug Abuse | 2024 | $2,814,796 | September 30, 2022 | August 31, 2027 | HOPPE, JASON | reporter.nih.gov |
| Noninvasive Brain Stimulation for Treating Addiction (Supplement) | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,814,672 | September 30, 2019 | August 31, 2025 | WAGNER, TIMOTHY ANDREW | reporter.nih.gov |
| Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,813,188 | September 10, 2022 | July 31, 2027 | YAN, BINGFANG | reporter.nih.gov |
| Characterization of Novel Neural Respiratory Circuit to Counter Opioid-Induced Respiratory Depression | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,804,236 | July 1, 2020 | May 31, 2026 | LU, DANIEL | reporter.nih.gov |
| Unpacking Disparities in Opioid Use Disorder Treatment Quality | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,800,158 | September 30, 2022 | July 31, 2027 | DOMINO, MARISA ELENA | reporter.nih.gov |
| Brain-penetrant GPR88 agonists as novel therapeutics for opioid abuse | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,795,026 | August 1, 2022 | July 31, 2027 | JACKSON, MICHAEL | reporter.nih.gov |
| Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,790,999 | May 1, 2021 | February 28, 2027 | BRUEHL, STEPHEN | reporter.nih.gov |
| Predict to Prevent: Dynamic Spatiotemporal Analyses of Opioid Overdose to Guide Pre-Emptive Public Health Responses | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,786,810 | May 15, 2022 | March 31, 2027 | STOPKA, THOMAS J | reporter.nih.gov |
| Adapting Web-based CBT to improve adherence and outcome for individuals with opioid use disorder and chronic pain treated with opioid agonists | NIH | National Center for Complementary & Integrative Health | 2022 to 2024 | $2,785,965 | June 1, 2022 | February 28, 2026 | HEAPY, ALICIA | reporter.nih.gov |
| Contributions of aberrant synaptic protein monoaminylation to opiate use disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,783,057 | August 15, 2022 | May 31, 2027 | MAZE, IAN S. | reporter.nih.gov |
| Mechanism and Countermeasure of Fentanyl-Induced Sudden Death | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,782,566 | January 1, 2023 | November 30, 2026 | XU, FADI | reporter.nih.gov |
| Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,779,659 | May 15, 2021 | March 1, 2025 | WEISBERG, RISA B | reporter.nih.gov |
| From Workforce Diversity to Key Cultural Competency Strategies to End Racial Disparities in Opioid Treatment Outcomes Across the Nation | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $2,776,409 | December 1, 2020 | November 30, 2026 | HOWARD, DANIEL L | reporter.nih.gov |
| Weighting Longitudinal Data to Access Opioid Analgesia Tapering Outcomes among Patients with Co-occurring Chronic Pain and Substance Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,773,978 | September 30, 2022 | July 31, 2027 | QEADAN, FARES | reporter.nih.gov |
| Single-cell resolution analysis of chromatin accessibility and gene expression changes in a model of drug addiction | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,772,633 | May 1, 2020 | February 28, 2026 | TELESE, FRANCESCA | reporter.nih.gov |
| Dynamic epigenomic landscape of opioid abuse following early-life adversity | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,755,296 | July 1, 2022 | April 30, 2027 | MAHLER, STEPHEN VINCENT | reporter.nih.gov |
| Opioid Policy Model | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,750,956 | April 1, 2020 | January 31, 2026 | BOBASHEV, GEORGIY | reporter.nih.gov |
| Linking VA and non-VA data to study the risk of suicide in chronic pain patients. | NIH | National Institute of Mental Health | 2021 to 2024 | $2,750,827 | August 10, 2020 | May 31, 2025 | PATHAK, JYOTISHMAN | reporter.nih.gov |
| Sex differences in the neural correlates underlying impairments in response inhibition and salience attribution in cocaine addiction | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,749,037 | April 1, 2020 | February 28, 2025 | GOLDSTEIN, RITA Z | reporter.nih.gov |
| Effectiveness of a CBT-based mHealth Intervention Targeting MOUD Retention, Adherence, and Opioid Use | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $2,748,195 | September 28, 2019 | November 30, 2025 | GLASNER, SUZETTE V | reporter.nih.gov |
| MOUD Comparative Effectiveness Study | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,740,436 | July 1, 2021 | April 30, 2027 | LAROCHELLE, MARC | reporter.nih.gov |
| Lasting Neurological Effects of Perinatal Opioids | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,739,816 | September 30, 2022 | July 31, 2027 | LOBO, MARY KAY | reporter.nih.gov |
| Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,732,942 | July 15, 2020 | April 30, 2026 | GUMMULURU, SURYARAM | reporter.nih.gov |
| Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment for Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,721,942 | September 30, 2022 | July 31, 2027 | COOPERMAN, NINA | reporter.nih.gov |
| Decoding the grammar of transcriptional enhancers regulating different stages of opioid use disorder | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,717,399 | September 30, 2020 | July 31, 2026 | TELESE, FRANCESCA | reporter.nih.gov |
| Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidity | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,714,944 | August 15, 2022 | May 31, 2027 | HAUSER, KURT F | reporter.nih.gov |
| Administrative Supplement: Medical Marijuana, Pain, and Opioid Use in Patients with Chronic Non-cancer Pain | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,712,570 | September 30, 2021 | June 30, 2026 | GILMAN, JODI | reporter.nih.gov |
| Community Driven Substance Use Recovery for High Opioid Overdose Areas | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,706,416 | September 23, 2021 | May 31, 2027 | BELLAMY, CHYRELL DENISE | reporter.nih.gov |
| Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,703,831 | September 30, 2019 | May 31, 2026 | HEIDBREDER, CHRISTIAN ARTHUR | reporter.nih.gov |
| Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose | NIH | National Institute on Drug Abuse | 2025 | $2,694,009 | September 1, 2023 | August 31, 2028 | LEVIN, HOWARD | reporter.nih.gov |
| Epigenomic labeling of cells that drive drug abuse behavior | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,685,000 | August 15, 2021 | June 30, 2027 | RENTHAL, WILLIAM RUSSELL | reporter.nih.gov |
| Enhancing Exercise and Psychotherapy to Treat Comorbid Addiction and Pain for ImprovingAdherence to Medication Assisted Treatment in Opioid Use Disorders | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $2,684,192 | September 28, 2019 | November 30, 2025 | NOCK, NORA L. | reporter.nih.gov |
| Transcriptional, functional, and circuit profiling at single cell resolution of neuronal ensembles engaged by heroin relapse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,676,252 | July 1, 2021 | March 31, 2026 | STUBER, GARRET D | reporter.nih.gov |
| Strengthening Addiction Care Continuum through Community Consortium in Vietnam | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,668,807 | September 30, 2021 | October 31, 2026 | LI, LI | reporter.nih.gov |
| Clinical Scientists Training Program in Addictions at MUSC | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,666,275 | January 15, 2013 | March 31, 2028 | MCRAE-CLARK, AIMEE L | reporter.nih.gov |
| Regulation of Gene Expression in the Human Habenula in Comorbid Opioid Addiction and Depression | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,665,324 | July 1, 2022 | April 30, 2027 | MAYNARD, KRISTEN ROSE | reporter.nih.gov |
| Development of negative allosteric modulators at the mu opioid receptor | NIH | National Institute on Drug Abuse | 2025 | $2,664,000 | September 1, 2025 | August 31, 2027 | MAJUMDAR, SUSRUTA | reporter.nih.gov |
| Chemistry and Pharmacology of Iboga Alkaloids | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,661,356 | June 15, 2020 | December 31, 2025 | SAMES, DALIBOR | reporter.nih.gov |
| A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement) | NIH | National Institute on Drug Abuse | 2022 to 2023 | $2,661,063 | November 1, 2023 | September 29, 2025 | MCNEIL, RYAN | reporter.nih.gov |
| Strategies to define and mitigate the placental and fetal alterations caused by maternal oxycodone exposure | NIH | National Institute on Drug Abuse | 2023 | $2,655,006 | August 1, 2023 | July 31, 2026 | HARRIS, LYNDA KATHERINE | reporter.nih.gov |
| The influence of neighborhood factors and social determinants of health on OUD treatment outcomes | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,649,504 | September 1, 2022 | August 31, 2025 | MAGIDSON, JESSICA F | reporter.nih.gov |
| Assessing a Clinically-meaningful Opioid Withdrawal Phenotype | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,633,151 | May 15, 2021 | February 28, 2026 | DUNN, KELLY E | reporter.nih.gov |
| A network-based, mixed methods study to identify and support multiple overdose responders and inform overdose prevention interventions | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,631,207 | September 30, 2022 | July 31, 2027 | WAGNER, KARLA D. | reporter.nih.gov |
| Genetic Variation in Opioid Induced Respiratory Depression in Mice | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,624,578 | April 1, 2020 | January 31, 2026 | BUBIER, JASON A | reporter.nih.gov |
| mHealth for Patient Self-Management of Opioid Use Disorder - Administrative Supplement | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,622,062 | September 14, 2018 | August 31, 2024 | POTTER, JENNIFER SHARPE | reporter.nih.gov |
| Workforce and System Change to Treat Adolescent Opioid Use Disorder within Integrated Pediatric Primary Care | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,621,447 | September 30, 2023 | August 31, 2028 | HULVERSHORN, LESLIE A. | reporter.nih.gov |
| Administrative Supplement: Peer Navigators for the ACT NOW OBOE Study | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $2,621,089 | September 20, 2019 | June 30, 2024 | BANN, CARLA M | reporter.nih.gov |
| Coordinated medical treatment of opioid use disorder and infectious disease | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $2,615,182 | July 18, 2019 | June 30, 2024 | SPRINGER, SANDRA ANN | reporter.nih.gov |
| Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,613,643 | August 1, 2019 | May 31, 2026 | MONTANER, LUIS J | reporter.nih.gov |
| Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdose | NIH | National Institute on Drug Abuse | 2025 | $2,612,736 | September 15, 2025 | July 31, 2028 | BARRETT, ANDREW | reporter.nih.gov |
| Recruitment for the efficacy trial of Tele-Harm Reduction in a federally qualified health center operated syringe services program | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,609,496 | May 1, 2021 | April 30, 2026 | TOOKES, HANSEL EMORY | reporter.nih.gov |
| Improving Access and Treatment for Co-occurring Opioid Use Disorders and Mental Illness | NIH | National Institute of Mental Health | 2022 to 2024 | $2,601,753 | September 12, 2019 | February 28, 2026 | WATKINS, KATHERINE E | reporter.nih.gov |
| Varieties of Impulsivity in Opiate and Stimulant Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,598,683 | July 15, 2008 | May 31, 2027 | VASSILEVA, JASMIN L | reporter.nih.gov |
| Risk Factors for AIDS among persons who inject drugs: HIV transmission during and after the pandemic | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,592,727 | September 10, 1994 | May 31, 2027 | MCKNIGHT, COURTNEY | reporter.nih.gov |
| Large Data Spatiotemporal Modeling of Optimal Combinations of Interventions to Reduce Opioid Harm in the United States | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,586,219 | September 30, 2022 | June 30, 2027 | CERDA, MAGDALENA | reporter.nih.gov |
| Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorderand Tolerance in the Treatment of Pain | NIH | National Institute on Drug Abuse | 2023 | $2,579,875 | September 1, 2023 | August 31, 2025 | MEYN, MALCOLM A | reporter.nih.gov |
| Culturally-responsive community-driven substance use recovery for Black and Latinx populations | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $2,579,630 | September 1, 2022 | August 31, 2023 | BELLAMY, CHYRELL DENISE | reporter.nih.gov |
| Improving Access to Naloxone to Prevent Opioid Overdose Deaths Within Community-based Programs that Serve People Who Use Drugs | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,575,705 | September 15, 2022 | June 30, 2027 | LAMBDIN, BARROT HOPKINS | reporter.nih.gov |
| HEAL Initiative: Coordinating Center to Support NIDA Preventing Opioid Use Disorder in Older Adolescents and Young Adults | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,575,479 | September 30, 2019 | August 31, 2027 | GRAHAM, PHILLIP W | reporter.nih.gov |
| Role of hypocretin in opiate addiction and withdrawal | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,572,776 | September 30, 2020 | June 30, 2025 | SIEGEL, JEROME M | reporter.nih.gov |
| Neurobiological Consequences of Long-Term Opioid Therapy in the Brain and Spinal Cord | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,571,829 | September 30, 2022 | June 30, 2027 | MARTUCCI, KATHERINE THERESA | reporter.nih.gov |
| Signaling balance and opioid dependence | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,569,274 | September 30, 2022 | August 31, 2027 | WHISTLER, JENNIFER L | reporter.nih.gov |
| Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,568,075 | May 1, 2020 | January 31, 2026 | MOELLER, FREDERICK GERARD | reporter.nih.gov |
| Enhancing Effectiveness Research on Recovery Housing for Persons Prescribed Medication for Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,560,524 | September 30, 2022 | July 31, 2027 | MERICLE, AMY ADALE | reporter.nih.gov |
| A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,557,655 | May 1, 2020 | January 31, 2026 | KAMPMAN, KYLE MATTHEW | reporter.nih.gov |
| Neural, endocrine, and behavioral markers of psychosocial stress predicting drug use outcomes in human opioid addiction | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,555,446 | May 1, 2021 | January 31, 2027 | MOELLER, SCOTT J | reporter.nih.gov |
| Unintended Prolonged Opioid Use | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $2,552,781 | March 15, 2019 | August 31, 2024 | HOOTEN, W. MICHAEL | reporter.nih.gov |
| A Naloxone Parachute: Novel Wearable Dual-Sensor Regional Oximeter to Detect Opioid-Induced Hypoxia and Enable Emergent Naloxone Rescue | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,550,000 | May 1, 2022 | October 31, 2025 | HITE, DESISLAVA ZLATANOVA | reporter.nih.gov |
| Uncovering links between neuronal transcriptomic and functional profiles in opioid addiction | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,548,788 | September 1, 2020 | July 31, 2025 | SJULSON, LUCAS L | reporter.nih.gov |
| IND-enabling development of a long-duration antagonist to treat opioid overdose | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,545,988 | September 15, 2023 | February 28, 2027 | ZANA, LAWRENCE J | reporter.nih.gov |
| Vital Signs In Opioid-Exposed Neonates | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $2,545,713 | September 24, 2021 | August 31, 2026 | AMBALAVANAN, NAMASIVAYAM | reporter.nih.gov |
| Research Examining Factors Associated with the Opioid Crisis among Underserved African Americans (REFOCUS) | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,545,081 | September 30, 2020 | July 31, 2025 | STEVENS-WATKINS, DANELLE J | reporter.nih.gov |
| Effect of methadone on the developmental properties of human brain organoids | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,543,335 | May 15, 2022 | February 28, 2027 | HADDAD, GABRIEL G | reporter.nih.gov |
| Novel Econometric Research Designs (NERD) to Help End Addiction Long-term | NIH | National Institute on Drug Abuse | 2024 | $2,542,500 | September 1, 2024 | August 31, 2027 | JALALI, ALI | reporter.nih.gov |
| Role of disability and pain in opioid overdose: mechanism and risk mitigation | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,540,888 | March 1, 2022 | January 31, 2027 | RUDOLPH, KARA ELIZABETH | reporter.nih.gov |
| A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders. | NIH | National Institute on Drug Abuse | 2022 to 2023 | $2,533,371 | September 15, 2022 | August 31, 2025 | SCHIFFER, FREDRIC | reporter.nih.gov |
| Novel Therapeutic Agents to Reverse Opioid Overdose | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,529,335 | September 30, 2020 | August 31, 2025 | LI, XINHUA | reporter.nih.gov |
| Medicaid Managed Care Coverage and Utilization Management of Opioid Use Disorder Treatment | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,528,947 | July 1, 2021 | May 31, 2026 | ANDREWS, CHRISTINA MARIE | reporter.nih.gov |
| Design and analysis advances to improve generalizability of clinical trials for treating opioid use disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,525,705 | September 15, 2022 | June 30, 2027 | RUDOLPH, KARA ELIZABETH | reporter.nih.gov |
| Mechanisms of prenatal opioid exposure on brain and behavior | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,525,552 | July 1, 2022 | April 30, 2027 | WU, PING | reporter.nih.gov |
| Genomic mechanisms of decision-making and opioid use trajectories in the rat | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,515,987 | September 30, 2020 | July 31, 2025 | DILEONE, RALPH J | reporter.nih.gov |
| The Effects of States' Substance Use Waivers on Healthcare Utilization and Opioid-related Overdoses Among Medicaid Enrollees with Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,513,313 | July 1, 2021 | May 31, 2026 | LINDNER, STEPHAN REINHARD | reporter.nih.gov |
| Insurance-related barriers to medications for opioid use disorder in private and Medicaid plans | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,512,669 | September 30, 2022 | July 31, 2027 | CHUA, KAO-PING | reporter.nih.gov |
| Immune Network Dysregulation of the Central Nervous System with HIV Persistence and Opioid Abuse | NIH | National Institute on Drug Abuse | 2022 | $2,512,500 | May 15, 2022 | April 30, 2026 | ZHANG, LE | reporter.nih.gov |
| When pandemics collide: The intersection of the opioid crisis, COVID-19 and HIV pandemics among people who inject drugs in the United States | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,512,373 | September 30, 2020 | August 31, 2025 | GENBERG, BECKY LYNN | reporter.nih.gov |
| Genomic profiling mediating the protective effect of social reward on opioid craving | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,512,064 | August 1, 2022 | June 30, 2027 | VENNIRO, MARCO | reporter.nih.gov |
| Development of an oral analgesic with reduced liabilities | NIH | National Institute on Drug Abuse | 2022 to 2023 | $2,500,000 | April 15, 2022 | March 31, 2025 | GEHLERT, DONALD R | reporter.nih.gov |
| Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults | NIH | National Institute on Drug Abuse | 2024 | $2,498,125 | August 1, 2019 | April 30, 2026 | LEE, JOSHUA D | reporter.nih.gov |
| Delivering Transcutaneous Auricular Neurostimulation as an Adjunct Treatment for Neonatal Opioid Withdrawal Syndrome | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,497,663 | September 30, 2019 | August 31, 2025 | KHODAPARAST, NAVID | reporter.nih.gov |
| The Impact of Opioids on Health Outcomes for Hospitalized Infants | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,495,528 | March 1, 2022 | February 28, 2027 | KELLEY-QUON, LORRAINE I | reporter.nih.gov |
| Delivering Transcutaneous Auricular Neurostimulation to Improve Treatment Retention in Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,493,400 | August 1, 2021 | July 31, 2025 | KHODAPARAST, NAVID | reporter.nih.gov |
| Multiomic profiling of cell types mediating opioid use disorder in rats | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,491,424 | August 15, 2022 | April 30, 2027 | TELESE, FRANCESCA | reporter.nih.gov |
| Wearable sensor for opioids detection based on electrochemical sensor arrayintegrated with Bluetooth device | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,489,927 | September 30, 2020 | August 31, 2025 | LEVITSKY, IGOR A | reporter.nih.gov |
| Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,484,468 | September 30, 2019 | April 30, 2027 | MOLOKANOVA, ELENA | reporter.nih.gov |
| Take-home expansion: Scope and impact study (THESIS) | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,483,369 | September 30, 2022 | June 30, 2027 | GRYCZYNSKI, JAN | reporter.nih.gov |
| Testing the Effects of Contingency Management and Behavioral Economics on Buprenorphine-Naloxone Treatment Adherence Using a Sequential Multiple Assignment Randomized Trial (SMART) Design | NIH | National Center for Complementary & Integrative Health | 2021 | $2,477,571 | September 28, 2019 | September 19, 2025 | DEREFINKO, KAREN J | reporter.nih.gov |
| Collaborative Hub for Emerging Adult Recovery Research (CHEARR) | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,473,645 | September 30, 2022 | July 31, 2027 | ZAJAC, KRISTYN | reporter.nih.gov |
| Single-Cell Dissection of Ensembles and Cell Types Mediating Opioid Action in the Rodent Brain | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,466,520 | June 1, 2021 | February 28, 2027 | HEIMAN, MYRIAM | reporter.nih.gov |
| Taking Our Shot: Extended-Release Naltrexone as Opioid Overdose Pre-Exposure Prophylaxis (PrEP) in People Using Stimulants Living With or At Risk of HIV | NIH | National Institute on Drug Abuse | 2024 | $2,460,000 | July 1, 2024 | June 30, 2028 | APPA, AYESHA A | reporter.nih.gov |
| Intervening with Opioid-Dependent Mothers Living in Poverty: Effects on Mothers' and Infants' Behavioral and Biological Regulation | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,456,632 | April 1, 2020 | March 31, 2026 | DOZIER, MARY | reporter.nih.gov |
| Molecular Networks and Deep Learning for Targeted HIV Interventions among PWID | NIH | National Institute on Drug Abuse | 2022 | $2,456,250 | April 15, 2022 | March 31, 2026 | CLIPMAN, STEVEN J. | reporter.nih.gov |
| Mapping opioid-dependence state transitions across structural, functional, and transcriptomic topologies | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,445,782 | September 30, 2021 | May 31, 2026 | BLENDY, JULIE A | reporter.nih.gov |
| Heroin-Induced genomic regulation of Ventral Pallidum neuron subtypes | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,439,544 | August 1, 2020 | May 31, 2025 | DIETZ, DAVID M | reporter.nih.gov |
| Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,437,500 | May 1, 2019 | April 30, 2025 | ALBARRACIN, DOLORES | reporter.nih.gov |
| A binational cohort of the intersection between substance use, HIV, and associated comorbidities among people who inject drugs in San Diego, CA | NIH | National Institute on Drug Abuse | 2025 | $2,437,310 | July 15, 2025 | May 31, 2030 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Social safety net programs as interventions to reduce opioid-related harms in reproductive-age women | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,434,940 | September 30, 2023 | August 31, 2028 | MARTINS, SILVIA SABOIA | reporter.nih.gov |
| DAT-Emulating target trials with big data to strengthen the evidence base for the clinical management of opioid use disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,434,754 | March 15, 2021 | January 31, 2027 | NOSYK, BOHDAN | reporter.nih.gov |
| Effectiveness and impact of counseling enhanced with electronic cigarettes for harm reduction in smokers with opioid use disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,424,067 | August 15, 2022 | April 30, 2027 | EL-SHAHAWY, OMAR | reporter.nih.gov |
| Ventral pallidal transcriptional adaptations underlying punishment-resistant opioid intake | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,423,094 | September 30, 2023 | May 31, 2028 | CREED, MEAGHAN C | reporter.nih.gov |
| Measuring Improvement in the Quality of ED-initiated Treatment for OUD using Observation | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,417,547 | August 1, 2020 | July 31, 2025 | MCCORMACK, RYAN P | reporter.nih.gov |
| Project STEPuP: A prenatal provider education and training program to improve medication-assisted treatment use during pregnancy and maternal and child health outcomes | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,403,019 | July 15, 2020 | April 30, 2026 | KRANS, ELIZABETH E | reporter.nih.gov |
| Genetic, Social, and Developmental Epidemiology of Drug Use Disorders | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,398,722 | March 15, 2010 | December 31, 2026 | KENDLER, KENNETH SEEDMAN | reporter.nih.gov |
| Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024 | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,395,895 | July 1, 2019 | April 30, 2026 | HASIN, DEBORAH S | reporter.nih.gov |
| Creating a novel place-based measure to explain geographic variability in naloxone access to reduce opioid overdose deaths | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,391,879 | September 26, 2022 | June 30, 2027 | CARPENTER, DELESHA MILLER | reporter.nih.gov |
| Development of a novel OTC naloxone product to be affordably priced and widely accessible | NIH | National Institute on Drug Abuse | 2021 | $2,381,970 | September 30, 2021 | June 30, 2023 | MATHAI, ASHANTHI | reporter.nih.gov |
| Multi-organ human-on-a-chip system to address overdose and acute and chronic efficacy and off-target toxicity | NIH | National Center for Advancing Translational Sciences | 2021 | $2,381,424 | September 27, 2019 | July 31, 2025 | HICKMAN, JAMES J | reporter.nih.gov |
| Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool. | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $2,380,820 | September 26, 2019 | July 31, 2025 | MAIDMENT, NIGEL T | reporter.nih.gov |
| Effects of Medication for Opioid Use Disorder on Microglial Activation and Neurocognition in People Living with HIV | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,375,783 | July 1, 2024 | April 30, 2029 | FARHADIAN, SHELLI | reporter.nih.gov |
| Neurocircuitry of clinical insight predicting relapse outcomes in opioid addiction | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,363,417 | September 1, 2020 | June 30, 2026 | MOELLER, SCOTT J | reporter.nih.gov |
| Domain-specific inhibition of angiotensin-converting enzyme as a therapeutic strategy for opioid use disorders | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,360,684 | July 1, 2022 | June 30, 2027 | ROTHWELL, PATRICK | reporter.nih.gov |
| Integrative single-cell spatial transcriptomic, anatomical, and functional profiling of brain-wide ensembles engaged by opioid relapse | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,359,515 | September 30, 2023 | June 30, 2028 | GOLDEN, SAM | reporter.nih.gov |
| Kentucky Outreach Service Kiosk (KyOSK): Reducing Overdose, Hepatitis C, and Other Drug-related Risks in Rural Appalachia through Health Kiosks | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,359,307 | August 15, 2022 | June 30, 2027 | YOUNG, APRIL MARIE | reporter.nih.gov |
| Role of novel VTA neurons in addiction-related behaviors | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,357,895 | April 1, 2014 | January 31, 2029 | HNASKO, THOMAS | reporter.nih.gov |
| Predicting fatal and non-fatal overdose in Los Angeles County with Rapid Overdose Surveillance Dashboard to target street-based addiction treatment and harm reduction services | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,355,267 | September 30, 2022 | August 31, 2027 | SHOVER, CHELSEA LEIGH | reporter.nih.gov |
| Translating CBD Treatment for Heroin Addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,349,864 | August 1, 2019 | June 30, 2025 | HURD, YASMIN L. | reporter.nih.gov |
| Examining the Impact of the Twin Epidemics of Methamphetamine and Opioid Use on Overdose, Risky Sex and Treatment Engagement among PWUD in Two Rural Appalachian Cohorts | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,345,140 | September 1, 2012 | March 31, 2028 | HAVENS, JENNIFER R | reporter.nih.gov |
| The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta Project (OPIOID BPP) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $2,337,729 | September 1, 2023 | August 31, 2026 | KELLY, JEANNIE CHEN | reporter.nih.gov |
| Digital treatments for opioids and other substance use disorders (DIGITS) in primary care: Observational Analysis of Adaptions to the Intervention | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,336,490 | April 1, 2019 | February 28, 2025 | GLASS, JOSEPH EDWIN | reporter.nih.gov |
| The impact of early life opioid exposure on the molecular and functional trajectories of septal cell types | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,334,521 | September 30, 2023 | June 30, 2028 | HARWELL, COREY C | reporter.nih.gov |
| Expanding Medication Assisted Therapies in Central Asia | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,333,300 | September 1, 2022 | June 30, 2027 | ALTICE, FREDERICK LEWIS | reporter.nih.gov |
| Community-Based Opioid Treatment (CBOT): Development and testing of a novel nurse-led model to deliver opioid use disorder treatment and HIV prevention and care in the community setting. | NIH | National Institute on Drug Abuse | 2025 | $2,332,500 | June 15, 2025 | May 31, 2029 | HEIDARI, OMEID | reporter.nih.gov |
| An investigation of low-intensity focused ultrasound for addiction | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,328,221 | March 1, 2022 | December 31, 2026 | LYNCH, WENDY JEAN | reporter.nih.gov |
| Examining the synergistic effects of cannabis and prescription opioid policies on chronic pain, opioid prescribing, and opioid overdose | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,319,128 | January 1, 2019 | November 30, 2025 | CERDA, MAGDALENA | reporter.nih.gov |
| Identification of small molecules that regulate endogenous opioid signaling by inhibiting angiotensin converting enzyme | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,301,877 | September 1, 2022 | July 31, 2027 | MORE, SWATI S | reporter.nih.gov |
| Integrating Multiple Omics to Illuminate Gene Networks Underlying Cigarette Smoking and Opioids. | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,298,081 | September 30, 2020 | June 30, 2026 | HANCOCK, DANA B | reporter.nih.gov |
| NLRP inflammasome directed activation of the innate immune system produces synaptic damage in EcoHIV infected mice self-administering fentanyl | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,296,200 | July 1, 2020 | April 30, 2026 | HAUGHEY, NORMAN J | reporter.nih.gov |
| Opioids and Maternal Brain-Behavior Adaptation During the Early Postpartum | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,290,094 | September 30, 2019 | July 31, 2025 | SWAIN, JAMES EDWARD | reporter.nih.gov |
| Multi-modal profiling of spatially resolved cell types mediating opioid withdrawal | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,285,817 | September 30, 2023 | May 31, 2028 | CHEN, XIAOKE | reporter.nih.gov |
| Novel mechanisms for correcting opioid-induced synaptic abnormalities | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,281,569 | August 15, 2021 | April 30, 2026 | WEMMIE, JOHN A | reporter.nih.gov |
| Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,275,105 | September 30, 2019 | December 31, 2023 | RUFF, MICHAEL R | reporter.nih.gov |
| Organizational factors associated with quality of care for opioid use disorders among transition-age adults in Medicaid | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,271,890 | April 15, 2023 | February 28, 2028 | NEIGHBORS, CHARLES J | reporter.nih.gov |
| Predicting neonatal health outcomes from placental and fetal brain extracellular vesicles in pregnant opioid users | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $2,267,819 | September 1, 2023 | August 31, 2026 | VOJTECH, LUCIA N | reporter.nih.gov |
| The Cascade of Care for Medicaid-Enrolled Youth with Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,267,501 | September 15, 2022 | July 31, 2027 | HADLAND, SCOTT EVAN | reporter.nih.gov |
| Impact of a Maryland Law Requiring Jails to Provide Medications for Opioid Use Disorder on Recently Incarcerated People. | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,266,406 | July 1, 2023 | May 31, 2027 | KENNEDY HENDRICKS, ALENE | reporter.nih.gov |
| Regulation of Neuronal GPCR Signaling | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,263,615 | September 15, 2014 | October 19, 2025 | MARTEMYANOV, KIRILL A. | reporter.nih.gov |
| Non-opiate topical formulations for treating pain associated with molar extractions | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $2,257,823 | September 18, 2018 | February 29, 2024 | PARR, ALAN | reporter.nih.gov |
| The Impact of Community Infrastructure Reinvestment Programs on Opioid Misuse and Opioid Overdose | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,257,300 | September 30, 2023 | August 31, 2028 | NESOFF, ELIZABETH | reporter.nih.gov |
| Amygdala kappa opioid system involvement in opioid relapse in pain states | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,256,959 | May 1, 2022 | February 28, 2027 | CAHILL, CATHERINE M | reporter.nih.gov |
| Impact of Medicaid Prescription Cap Policies on Treatment Outcomes for Opioid Use Disorder: A National Mixed Methods Study | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,254,212 | April 1, 2023 | February 29, 2028 | HUGHTO, JACLYN WHITE | reporter.nih.gov |
| Neuroimaging response inhibition and salience attribution changes during mindfulness-based treatment of human heroin addiction | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $2,253,926 | August 15, 2019 | June 30, 2024 | GOLDSTEIN, RITA Z | reporter.nih.gov |
| Impact of prescription stimulants on the drug overdose epidemic | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,253,245 | May 1, 2023 | March 31, 2028 | DE NADAI, ALESSANDRO STEVENS | reporter.nih.gov |
| The Rhode Island Young Adult Prescription and Illicit Drug Study (RAPIDS): Responding to Fentanyl and Associated Harms | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,243,163 | August 15, 2019 | May 31, 2025 | MARSHALL, BRANDON DAVID LEWIS | reporter.nih.gov |
| Increased CNS Opioid Exposure by an Acetaminophen-Induced Blood-Brain Barrier Mechanism | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,240,104 | July 1, 2020 | May 31, 2026 | DAVIS, THOMAS PAUL | reporter.nih.gov |
| Reducing Drug-Related Mortality Using Predictive Analytics: A Randomized, Statewide, Community Intervention Trial | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,236,493 | September 30, 2019 | July 31, 2025 | MARSHALL, BRANDON DAVID LEWIS | reporter.nih.gov |
| Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,227,803 | April 1, 2019 | March 31, 2026 | CRANE, HEIDI M. | reporter.nih.gov |
| Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA) | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,227,530 | September 30, 2023 | July 31, 2028 | NESE, RHONDA | reporter.nih.gov |
| Kratom alkaloids: in vitro and in vivo pharmacological mechanisms | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,226,033 | April 15, 2019 | February 28, 2025 | MCCURDY, CHRISTOPHER R | reporter.nih.gov |
| A Big Data Approach to Identify Epigenetic, Transcriptomic, and Network Dynamics as Immune Dysfunction Drivers Associated with HIV Infection and Substance Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,218,325 | July 15, 2020 | May 31, 2025 | GERSTEIN, MARK BENDER | reporter.nih.gov |
| Reversing opioid-induced hypoxemia with novel thiol-based drugs without compromising analgesia in goats | NIH | National Institute on Drug Abuse | 2022 | $2,218,043 | May 1, 2022 | April 30, 2026 | HODGES, MATTHEW ROBERT | reporter.nih.gov |
| Ghrelin Deacylase as a Treatment for Opioid Polysubstance Abuse | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,207,625 | July 1, 2022 | June 30, 2027 | ZHAN, CHANG-GUO | reporter.nih.gov |
| Selective Kv7.2/3 activators for the treatment of neuropathic pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $2,200,680 | September 1, 2021 | March 31, 2022 | SIGNORE, ARMANDO | reporter.nih.gov |
| Estimating the population size of persons who inject drugs in New York | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,200,197 | June 1, 2021 | December 13, 2022 | BRADLEY, HEATHER | reporter.nih.gov |
| Biased Kappa Opioid Agonists as Non-addictive Analgesics | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,199,015 | April 15, 2019 | August 31, 2025 | MARTIN, THOMAS JEFFREY | reporter.nih.gov |
| Endocannabinoid Targeting for Opioid Induced Respiratory Depression | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,190,554 | July 1, 2022 | June 30, 2027 | MILNES, TALLY MARIE | reporter.nih.gov |
| Substance use disorder treatment centers and facility ownership changes | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,189,663 | April 1, 2023 | February 29, 2028 | BUSCH, SUSAN H | reporter.nih.gov |
| Reversing Overdose Epidemics through Simulation, Collaboration, and Unified Efforts (RESCUE) | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,189,222 | September 15, 2024 | July 31, 2028 | ZANG, XIAO | reporter.nih.gov |
| Psychosocial and neurobiological stress and opioid use trajectories following pregnancy | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,185,441 | September 30, 2020 | July 31, 2025 | RUTHERFORD, HELENA JV | reporter.nih.gov |
| Changing our paths: Well-being and recovery among American Indians with opioid use disorder | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,182,842 | June 1, 2019 | May 31, 2026 | GREENFIELD, BRENNA | reporter.nih.gov |
| Mirtazapine for methamphetamine use disorder: drug-drug interaction study | NIH | National Institute on Drug Abuse | 2021 | $2,182,386 | June 1, 2020 | May 31, 2024 | COFFIN, PHILLIP O | reporter.nih.gov |
| Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,174,053 | February 15, 2019 | January 31, 2026 | STEIN, MICHAEL D | reporter.nih.gov |
| High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating Addiction | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,172,679 | May 15, 2022 | February 28, 2027 | OLSON, DAVID E | reporter.nih.gov |
| Impacts of universal access to HIV/AIDS care among HIV+ injection drug users | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,164,148 | September 17, 2007 | April 30, 2026 | MILLOY, M-J | reporter.nih.gov |
| Sex-specific mechanisms underlying the effects of pain on opioid seeking | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,163,671 | September 15, 2022 | June 30, 2027 | MORON-CONCEPCION, JOSE A | reporter.nih.gov |
| Social and behavioral determinants of MOUD utilization and opioid overdose | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,158,035 | August 1, 2023 | May 31, 2028 | YU, HONG | reporter.nih.gov |
| Impacts of structural and system-level interventions on HIV/STI and overdose epidemics among SWs | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,156,134 | July 15, 2010 | March 31, 2026 | KRUSI, ANDREA | reporter.nih.gov |
| Enhancing Infrastructure for Clinical and Translational Research to Address the Opioid Epidemic | NIH | National Center for Advancing Translational Sciences | 2021 to 2023 | $2,152,222 | August 6, 2019 | June 30, 2024 | LENERT, LESLIE A. | reporter.nih.gov |
| Elucidating High Oral Fluid Exposure Mechanisms of Buprenorphine to Reduce Dental Caries | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $2,144,215 | September 21, 2023 | September 20, 2028 | HU, MING | reporter.nih.gov |
| Delivery of Addiction Treatment for Medicaid Enrollees with Serious Injection-Related Infections | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,140,434 | September 30, 2023 | June 30, 2027 | KAPADIA, SHASHI | reporter.nih.gov |
| Assessment of fetal brain health via circulating exRNA carriers for opioid use disorder in pregnancy | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,139,591 | September 1, 2023 | June 30, 2028 | CHIU, DANIEL T | reporter.nih.gov |
| Randomized Clinical Trial Intervention to Treat Chronic Pain Among Persons Maintained on Methadone for Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,127,553 | June 1, 2022 | January 31, 2025 | ANTOINE, DENIS GODWIN | reporter.nih.gov |
| Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,125,460 | April 15, 2022 | February 28, 2027 | BABALONIS, SHANNA | reporter.nih.gov |
| Development of cannabinoid-opioid combination with opioid sparing and synergistic analgesic effects to prevent opioid use disorder and overdose. | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,110,556 | September 30, 2019 | August 31, 2025 | BRIONES, MARISA | reporter.nih.gov |
| Racial Equity in Systems to Treat Opioid Use Disorder for Everyone (RESTORE): A Pilot Randomized Controlled Trial | NIH | National Institute on Drug Abuse | 2023 to 2024 | $2,107,000 | September 1, 2023 | July 31, 2025 | SMILEY, SABRINA LYNN | reporter.nih.gov |
| Low-input profiling of brain-region and cell-type specific epigenomic dynamics to understand gene-environment interactions in opioid addiction | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,106,454 | September 15, 2023 | June 30, 2028 | LU, CHANG | reporter.nih.gov |
| Inflammasome activation in an SIV-ART model of chronic drug abuse | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,104,458 | September 30, 2019 | July 31, 2025 | VEENHUIS, REBECCA TERILLI | reporter.nih.gov |
| Repurposing FDA-approved oxytocin to treat opioid-induced respiratory depression | NIH | National Institute on Drug Abuse | 2025 | $2,104,389 | July 1, 2025 | June 30, 2027 | MENDELOWITZ, DAVID | reporter.nih.gov |
| Cellular Mechanisms and Therapeutic Potential of NR4A1 in Pain Resolution | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $2,103,564 | June 1, 2024 | May 31, 2027 | BERTA, TEMUGIN | reporter.nih.gov |
| Reduction of opioid requirement associated with Auriculo-nerve stimulation following open surgery | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,096,444 | August 1, 2022 | June 30, 2027 | CHELLY, JACQUES E. | reporter.nih.gov |
| Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals with OUD | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,080,730 | July 15, 2023 | May 31, 2028 | PECK, KELLY R. | reporter.nih.gov |
| Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,078,841 | August 1, 2021 | May 31, 2027 | JAMES, GEORGE ANDREW | reporter.nih.gov |
| DAT- Integrated Outpatient Treatment of Opioid Use Disorder and Injection-Related Infections | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,076,726 | September 30, 2020 | August 31, 2025 | FANUCCHI, LAURA | reporter.nih.gov |
| A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypes | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,072,058 | September 1, 2020 | June 30, 2024 | ZACHARIOU, VENETIA | reporter.nih.gov |
| The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions | NIH | National Institute of Mental Health | 2024 | $2,065,898 | September 12, 2019 | February 28, 2026 | MANDELL, DAVID S | reporter.nih.gov |
| Efficacy and implementation considerations for a peer-led motivational interviewing intervention to promote uptake of drug checking services and safer drug use behaviors to reduce overdose | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,053,801 | September 15, 2024 | May 31, 2029 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| An ethno-epidemiological study of the implementation and effectiveness of an innovative and comprehensive response to the evolving overdose epidemic | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,053,558 | July 1, 2017 | May 31, 2028 | KERR, THOMAS | reporter.nih.gov |
| Contextualized daily prediction of lapse risk in opioid use disorder by digital phenotyping | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,052,139 | August 1, 2019 | June 30, 2025 | CURTIN, JOHN J. | reporter.nih.gov |
| New psychoactive substance exposure among NYC nightclub and festival attendees | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,051,804 | August 15, 2023 | May 31, 2027 | PALAMAR, JOSEPH J | reporter.nih.gov |
| A Novel Opioid-Free Targeted Pain Control Method for Acute Post-Operative Localized Pain Related to Oral Surgical Procedures | NIH | National Institute of Dental & Craniofacial Research | 2023 | $2,050,357 | September 19, 2019 | September 18, 2025 | JADIA, RAHUL | reporter.nih.gov |
| Novel biologic to treat chemotherapy-induced neuropathic pain | NIH | National Cancer Institute | 2022 to 2023 | $2,049,964 | September 19, 2022 | August 31, 2025 | KOGAN, YAKOV | reporter.nih.gov |
| Examining opioid use disorder treatment in Medicaid managed care plans: policies and outcomes | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,048,744 | July 15, 2020 | April 30, 2026 | HODGKIN, DOMINIC | reporter.nih.gov |
| Influence of Orexin Antagonism on Opioid and Methamphetamine Demand | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,047,388 | April 15, 2023 | December 1, 2025 | STRICKLAND, JUSTIN CHARLES | reporter.nih.gov |
| Dopaminergic and Glutamatergic Mechanisms of Cocaine Addiction: Sex Differences | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,046,903 | April 1, 2008 | May 31, 2027 | LYNCH, WENDY JEAN | reporter.nih.gov |
| Neural Ice Technology for Treatment of Pain | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $2,045,816 | August 21, 2024 | July 31, 2027 | SIDOTI, CHARLES | reporter.nih.gov |
| Studies to Advance Recovery Supports (STARS) in Central Appalachia | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,041,100 | July 15, 2020 | April 30, 2026 | PACK, ROBERT P | reporter.nih.gov |
| Validation of a new large-pore channel as a novel target for neuropathic pain | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $2,039,202 | September 25, 2023 | August 31, 2026 | QIU, ZHAOZHU | reporter.nih.gov |
| Empowering dentists to reduce opioid prescriptions to young people | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $2,035,344 | January 1, 2023 | December 31, 2028 | OYLER, DOUGLAS | reporter.nih.gov |
| Impacts of morphine and HIV-Tat exposures and dimethylfumarate treatment on brain BDNF and mitochondrial and behavioral dysfunction. | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,031,347 | April 1, 2023 | January 31, 2028 | MCLAUGHLIN, JAY P. | reporter.nih.gov |
| Oxycodone, Neonatal Opioid Withdrawal Syndrome, and Adult Abuse Liability | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,030,768 | August 1, 2020 | May 31, 2026 | BYRNES, ELIZABETH M | reporter.nih.gov |
| Using the Genetic Architecture of Substance Use Disorders to Advance Gene Identification and Understanding of Pathways of Risk | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,028,660 | July 1, 2020 | April 30, 2026 | DICK, DANIELLE M | reporter.nih.gov |
| Evaluating Policy Interventions to Decrease Excessive and Risky Perioperative Opioid Prescribing | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,027,866 | September 1, 2022 | October 31, 2024 | WALJEE, JENNIFER FILIP | reporter.nih.gov |
| DAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,025,832 | May 15, 2019 | February 28, 2025 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| Identifying Genetic Variants Associated with Opioid Overdose Mortality | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,020,602 | July 1, 2018 | April 30, 2024 | NELSON, ELLIOT C | reporter.nih.gov |
| Increasing access to opioid use disorder treatment by opening pharmacy-based medication units of opioid treatment programs | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,012,459 | August 15, 2022 | May 31, 2026 | WU, LI-TZY | reporter.nih.gov |
| Estimating the cost of peer specialists providing comprehensive healthcare services at a syringe services program | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,007,015 | June 1, 2023 | March 31, 2028 | TOOKES, HANSEL EMORY | reporter.nih.gov |
| A mechanistic investigation of risk factors for opioid use disorder: Examining hippocampal-based context-dependent learning and memory associated with adverse childhood experiences | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,006,954 | September 15, 2023 | June 30, 2028 | DUVAL, ELIZABETH | reporter.nih.gov |
| Systems analysis and improvement to optimize opioid use disorder care quality and continuity for patients exiting jail (SAIA-MOUD). | NIH | National Institute of Nursing Research | 2023 | $2,004,931 | September 19, 2023 | August 31, 2026 | GIMBEL, SARAH ODELL | reporter.nih.gov |
| CADENCE - Continuous And Data-drivEN CarE | NIH | National Institute on Drug Abuse | 2024 | $1,996,547 | September 30, 2022 | September 29, 2027 | MARSHALL, JENNIFER | reporter.nih.gov |
| Integrated Treatment for Veterans with Co-Occurring Chronic Pain and Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,994,995 | September 30, 2019 | August 31, 2025 | WITKIEWITZ, KATIE A | reporter.nih.gov |
| Leveraging the plasma virome as a biological indicator of HIV risk and transmission networks among people who inject drugs | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,994,072 | June 1, 2023 | March 31, 2028 | KANDATHIL, ABRAHAM | reporter.nih.gov |
| The Impact of Surgery on Outcomes for Patients taking Medications for Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,993,837 | September 30, 2023 | June 30, 2028 | NGUYEN, THUY DIEU | reporter.nih.gov |
| Real time relapse risk scoring for Opioid Use Disorder (OUD) from clinical trial datasets | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,992,401 | August 1, 2023 | June 30, 2028 | LUO, SEAN XIAO | reporter.nih.gov |
| Developing and Evaluating a Machine-Learning Opioid Prediction & Risk-Stratification E-Platform (DEMONSTRATE) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,991,133 | July 1, 2021 | November 1, 2023 | LO-CIGANIC, WEI-HSUAN | reporter.nih.gov |
| Proof of concept study to treat negative affect in chronic low back pain | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $1,987,769 | September 26, 2019 | July 31, 2025 | WASAN, AJAY D | reporter.nih.gov |
| Fast-track: Scalable digital delivery of evidence-based training for addiction professionals to maximize treatment admission and retention rates of opioid use disorder in affected families. | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,983,278 | July 15, 2022 | January 31, 2027 | MACKY, JANE | reporter.nih.gov |
| Understanding the Association between Sublingual Buprenorphine and Oral Health Outcomes | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $1,981,857 | September 21, 2023 | August 31, 2028 | ROJAS RAMIREZ, MARCIA VANESSA | reporter.nih.gov |
| Coaching Performance Driven Practice Change in the Context of Value Based Purchasing Under New York Medicaid | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,979,461 | July 15, 2019 | June 30, 2025 | NEIGHBORS, CHARLES J | reporter.nih.gov |
| TRANSCRIPTOME AND EPIGENOME MAPPING IN DOPAMINE NEURONS FROM THE OPIOID EXPOSED HUMAN BRAIN | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,979,365 | September 15, 2019 | June 30, 2024 | AKBARIAN, SCHAHRAM | reporter.nih.gov |
| Development of small molecule therapeutics for mitigating opioid withdrawal syndrome | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,975,277 | April 15, 2022 | August 31, 2027 | LABED, SID AHMED | reporter.nih.gov |
| Targeting the allosteric sodium site with novel probes for delta opioid receptor | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,974,675 | September 1, 2023 | April 30, 2028 | MAJUMDAR, SUSRUTA | reporter.nih.gov |
| Family-based Recovery Support Service Network for Youth OUD | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,971,213 | September 30, 2020 | August 31, 2025 | HOGUE, AARON | reporter.nih.gov |
| Inflammation associated with HIV infection: role of receptor cross-talk | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,971,180 | September 30, 2019 | June 30, 2025 | ROGERS, THOMAS J | reporter.nih.gov |
| Peer-based Retention of people who Use Drugs in Rural Research (PROUD-R2) | NIH | National Center for Advancing Translational Sciences | 2021 to 2023 | $1,971,059 | September 18, 2018 | July 31, 2024 | KORTHUIS, PHILIP TODD | reporter.nih.gov |
| Incentivized Collaborative Care to Desseminate Contingency Management | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,969,002 | September 30, 2021 | June 30, 2026 | GASTFRIEND, DAVID R | reporter.nih.gov |
| MINDER: Wearable sensor-based detection of digital biomarkers of adherence to medications for opioid use disorder | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,966,682 | June 6, 2023 | April 30, 2027 | CARREIRO, STEPHANIE P | reporter.nih.gov |
| Impact of Medicare Part D opioid safety policies on disabled beneficiaries before and during the COVID-19 pandemic | NIH | National Institute on Drug Abuse | 2022 to 2024 | $1,965,950 | August 15, 2022 | June 30, 2026 | WEN, HEFEI | reporter.nih.gov |
| IDENTIFYING EPIGENOMICS AND CONNECTOMICS OF PROTRACTED OPIOID WITHDRAWAL AND RELAPSE USING CELLULAR BARCODING | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,965,000 | August 1, 2022 | June 30, 2027 | KEBSCHULL, JUSTUS M | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Yale University | New Haven, CT | 73 | $203.5 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 32 | $123.1 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 67 | $101.9 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 45 | $82.1 million | 0 | $0 |
| Research Triangle Institute | Research Triangle Park, NC | 23 | $79.9 million | 0 | $0 |
| University of Washington | Seattle, WA | 53 | $74 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 35 | $69.8 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 38 | $67.9 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 37 | $60.5 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 39 | $50.6 million | 0 | $0 |
| Boston Medical Center | Boston, MA | 21 | $49 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 1 | $43.4 million | 0 | $0 |
| Ohio State University | Columbus, OH | 15 | $40.2 million | 0 | $0 |
| Washington University | Saint Louis, MO | 34 | $39.1 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 20 | $38.6 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 17 | $37.8 million | 0 | $0 |
| Brown University | Providence, RI | 19 | $36.5 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 35 | $36.3 million | 0 | $0 |
| Columbia University | New York, NY | 3 | $35.9 million | 0 | $0 |
| The Emmes Company, LLC | Rockville, MD | 1 | $33.4 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 24 | $33.3 million | 0 | $0 |
| Stanford University | Stanford, CA | 29 | $33 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 20 | $32.5 million | 0 | $0 |
| New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, INC | New York, NY | 15 | $32.4 million | 0 | $0 |
| Sparian Biosciences, Inc. | New York City, NY | 5 | $32 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 25 | $30.9 million | 0 | $0 |
| Rand Corporation | Santa Monica, CA | 17 | $30.4 million | 0 | $0 |
| Friends Research Institute, Inc. | Baltimore, MD | 15 | $29.1 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 16 | $28.8 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 11 | $28.4 million | 0 | $0 |
| National Collegiate Inventors and Innovators Alliance | Hadley, MA | 1 | $27.5 million | 0 | $0 |
| University of Florida | Gainesville, FL | 22 | $26.4 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 14 | $25.4 million | 0 | $0 |
| University of Chicago | Chicago, IL | 9 | $25.2 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 18 | $25.1 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 15 | $24.5 million | 0 | $0 |
| George Mason University | Fairfax, VA | 2 | $24.4 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 14 | $23.5 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 13 | $23 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 14 | $22.8 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 26 | $22.5 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 18 | $22.5 million | 0 | $0 |
| Hennepin Healthcare Research Institute | Minneapolis, MN | 1 | $22.4 million | 0 | $0 |
| Duke University | Durham, NC | 18 | $22.4 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 19 | $21.5 million | 0 | $0 |
| Psychogenics, Inc. | Paramus, NJ | 1 | $21.3 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 5 | $20.5 million | 0 | $0 |
| Rhode Island Hospital | Providence, RI | 16 | $20.5 million | 0 | $0 |
| Emory University | Atlanta, GA | 14 | $19.6 million | 0 | $0 |
| Nirsum Laboratories, Inc. | New York, NY | 3 | $19.1 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 25 | $18.1 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 13 | $18 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 13 | $16.7 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 9 | $16.1 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 7 | $16 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 3 | $15.6 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 14 | $15.5 million | 0 | $0 |
| Ensysce Biosciences, Inc. | La Jolla, CA | 2 | $15.4 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 16 | $14.7 million | 0 | $0 |
| Mclean Hospital | Belmont, MA | 11 | $14.2 million | 0 | $0 |
| Chestnut Health Systems, Inc. | Bloomington, IL | 10 | $14.2 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 11 | $14 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 13 | $13.6 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 18 | $13.1 million | 0 | $0 |
| University of New Mexico | Albuquerque, NM | 6 | $13 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 8 | $12.6 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 4 | $12.4 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 12 | $12.3 million | 0 | $0 |
| Clear Scientific, LLC | Cambridge, MA | 4 | $11.9 million | 0 | $0 |
| Lyndra Therapeutics, Inc. | Watertown, MA | 1 | $11.7 million | 0 | $0 |
| University of Oregon Eugene | Eugene, OR | 3 | $11.6 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 8 | $11.5 million | 0 | $0 |
| Magee-Women's Res Inst and Foundation | Pittsburgh, PA | 5 | $11 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 9 | $10.9 million | 0 | $0 |
| Cerevel Therapeutics, LLC | Cambridge, MA | 2 | $10.8 million | 0 | $0 |
| New York University | New York, NY | 6 | $10.4 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 6 | $10 million | 0 | $0 |
| University of British Columbia | Vancouver | 6 | $9.5 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 8 | $9.4 million | 0 | $0 |
| Lohocla Research Corporation | Aurora, CO | 1 | $9.3 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 6 | $9.1 million | 0 | $0 |
| Mebias Discovery, Inc. | Philadelphia, PA | 2 | $9 million | 0 | $0 |
| University of California at Davis | Davis, CA | 12 | $9 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 13 | $8.5 million | 0 | $0 |
| Astrazeneca Pharmaceuticals, LP | Wilmington, DE | 2 | $8.3 million | 0 | $0 |
| Uswm, LLC | Louisville, KY | 2 | $8.3 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 3 | $8.2 million | 0 | $0 |
| Baystate Medical Center, Inc. | Springfield, MA | 7 | $8.2 million | 0 | $0 |
| Washington State University | Pullman, WA | 6 | $8.1 million | 0 | $0 |
| Northeastern University | Boston, MA | 2 | $7.9 million | 0 | $0 |
| Indiana University | Bloomington, IN | 7 | $7.9 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 5 | $7.8 million | 0 | $0 |
| Simon Fraser University | Burnaby | 2 | $7.8 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 4 | $7.7 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 2 | $7.6 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 8 | $7.6 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 11 | $7.5 million | 0 | $0 |
| Akyso Therapeutics, LLC | Salisbury, MD | 2 | $7.4 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 4 | $7.2 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 6 | $7.1 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 851 | $619,575,343 | 0 | $0 |
| 2024 | 913 | $638,209,073 | 0 | $0 |
| 2023 | 896 | $657,357,258 | 0 | $0 |
| 2022 | 856 | $671,488,768 | 0 | $0 |
| 2021 | 746 | $653,589,658 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.